癌化学療法時の薬物間相互作用

出版社： 先端医学社
著者：
発行日： 1998-04-30
分野： 臨床医学：一般  >  癌/腫瘍一般
ISBN： 9784915892592
電子書籍版： 1998-04-30
電子書籍
章別単位で購入
ブラウザ、アプリ閲覧

2,585 円(税込)

購入する

商品紹介

実際的な観点から抗癌剤投与による薬物間相互作用を検証する
癌治療に携わる医師にとって、抗癌剤の「適応と限界」を見極めることは、重要な責務といえる。飛躍的進歩を遂げる癌化学療法の多剤併用療法を実際的な観点から、臨床薬理学，分類別抗癌剤の相互作用、各種疾患の薬物療法、緩和医療として重要な鎮痛薬、鎮痛補助薬、患者服薬指導までを詳述。癌医療の現場で役立つ座右の書。

目次

  • 表紙
  • 序
  • 執筆者一覧
  • 目次
  • Part1: 薬物間相互作用の基礎知識
  • 1 代謝過程における薬物間相互作用のメカニズム
  • はじめに
  • 1 薬物代謝とチトクロームP-450
  • 2 チトクロームP-450を介した薬物間相互作用
  • 3 同じチトクロームP-450分子種で代謝される薬物同士の併用による相互阻害
  • 4 チトクロームP-450と代謝物が複合体をつくることによる阻害
  • 5 チトクロームP-450のヘム部分への配位による阻害
  • 6 チトクロームP-450の誘導と薬物間相互作用
  • おわりに
  • 2 腎排泄過程における薬物間相互作用のメカニズム
  • はじめに
  • 1 糸球体濾過における相互作用
  • 2 尿細管分泌における相互作用
  • 1. 有機カチオン輸送系
  • 2. 有機アニオン輸送系
  • 3. P糖蛋白質
  • 3 尿細管再吸収における相互作用
  • 1. 薬物の受動的再吸収
  • 2. 薬物の能動的再吸収
  • おわりに
  • 3 肝移行過程における薬物間相互作用のメカニズム
  • はじめに
  • 1 肝臓の構造
  • 2 肝臓における取り込み
  • 1. 単純拡散による取り込み機構
  • 2. 肝臓における輸送担体を介した取り込み機構
  • 3 胆汁中排泄
  • 1. 再吸収のための輸送担体
  • 2. 胆管腔側胆汁酸輸送担体
  • 3. 胆管側多様認識性有機アニオン輸送担体(cMOAT)
  • 4. P糖蛋白質
  • おわりに
  • 4 消化管吸収過程における薬物間相互作用のメカニズム
  • はじめに
  • 1 消化管内pH変化による吸収変化
  • 2 胃内容排出速度の変化による吸収性の変化
  • 3 腸管内安定性変化による吸収性変化
  • 4 複合体形成による吸収阻害
  • 5 担体介在輸送の競合による吸収阻害
  • 6 消化管管腔内分泌抑制による吸収性増大
  • 7 小腸上皮細胞薬物代謝酵素競合による吸収性増大
  • おわりに
  • 5・臓器・組織(肝・腎・消化管以外)分布過程における薬物間相互作用のメカニズム
  • はじめに
  • 1 臓器・組織分布の変動要因
  • 2 蛋白結合の薬物問相互作用
  • 3 トランスポータによる細胞内取り込みと排出
  • 4 細胞内プールの要因となる内因性物質や受容体との結合
  • おわりに
  • 6 5-フルオロウラシル系抗癌剤とソリブジンの相互作用のメカニズム
  • はじめに
  • 1 抗癌剤による血液障害から死へのプロセス
  • 2 5-フルオロウラシルの体内動態に及ぼすソリブジンの効果
  • おわりに
  • Part2: 分類別抗癌剤の薬物間相互作用
  • 1 アルキル化薬
  • はじめに
  • 1 ナイトロジェンマスタード系薬剤
  • 1. シクロホスファミド
  • 2. イホスファミド
  • 3. メルファラン
  • 2 アジリジン系薬剤
  • 1. チオテパ
  • 3 アルキルスルホン酸系薬剤
  • 1. ブスルファン
  • 4 ニトロソウレア系薬剤
  • 5 トリアゼン系薬剤
  • 1. ダカルバジン
  • 2. プロカルバジン
  • 6 その他
  • 1. カルボコン
  • おわりに
  • 2 代謝拮抗薬I
  • はじめに
  • 1 シタラビン
  • 1. シタラビンの作用機序, 薬物動態, 薬物有害反応
  • 2. シタラビンの薬物間相互作用
  • 2 メトトレキサート
  • 1. メトトレキサートの作用機序, 薬物動態, 薬物有害反応
  • 2. メトトレキサートの薬物間相互作用
  • 3 6-メルカプトプリン
  • 1. 6-メルカプトプリンの作用機序, 薬物動態, 薬物有害反応
  • 2. 6-メルカプトプリンの薬物間相互作用
  • 4 ペントスタチン
  • 1. ペントスタチンの作用機序, 薬物動態, 薬物有害反応
  • 2. ペントスタチンの薬物間相互作用
  • おわりに
  • 3 代謝拮抗薬II
  • はじめに
  • 1 5-FUの作用機序と代謝
  • 1. 5-FUのRNA障害
  • 2. 5-FUのTS阻害
  • 2 5-FUと相互作用を有する薬物
  • 1. 5-FUのanabolismに関与する薬物
  • 2. 5-FUのcatabolismに関与する薬物
  • 3. その他の5-FUと相互作用を有する薬物
  • おわりに
  • 4 抗癌性抗生物質
  • はじめに
  • 1 アントラサイクリン系抗癌性抗生物質
  • 1. ドキソルビシン
  • 2. ダウノルビシン
  • 3. ピラルビシン
  • 4. イダルビシン
  • 5. ファルモルビシン
  • 6. アクラルビシン
  • 2 ブレオマイシン
  • 3 マイトマイシンC
  • 4 ダクチノマイシン
  • 5 ネオカルチノスタチン
  • おわりに
  • 5 植物アルカロイド
  • はじめに
  • 1 作用機序
  • 2 前臨床試験
  • 3 薬物動態(PK)と薬理作用(PD)
  • 4 代謝
  • 5 臨床効果
  • 1. 第I相試験
  • 2. 非小細胞肺癌
  • 3. 進行性乳癌
  • 4. その他の腫瘍の有効性
  • おわりに
  • 6 植物由来
  • はじめに
  • 1 カンプトテシン誘導体―トポイソメラーゼI阻害薬―
  • 1. 塩酸イリノテカン
  • 2. トポテカン
  • 2 ポドフィロトキシン誘導体―トポイソメラーゼII阻害薬―
  • 1. エトポシド
  • 3 タキサン誘導体
  • 1. パクリタキセル
  • 2. ドセタキセル
  • おわりに
  • 7 白金錯体
  • はじめに
  • 1 CDDP(CBDCA)+5-FU
  • 2 CDDP(CBDCA)+VP-16
  • 3 CDDP+BLM
  • 4 CDDP(CBDCA)+CPA
  • 5 CDDP+VDS
  • 6 CDDP+VCR+ADM+VP-16
  • 7 他剤併用時の薬物間相互作用
  • 1. 制吐薬
  • 2. 他の薬剤
  • おわりに
  • 8 その他の抗癌剤
  • はじめに
  • 1 L-アスパラギナーゼ
  • 2 ヒドロキシウレア
  • 3 シクロスポリン
  • おわりに
  • 9 非特異的免疫賦活剤
  • はじめに
  • 1 作用形態の特徴
  • 2 最近の作用機序の特徴
  • 3 術後補助療法施行時の相互作用
  • 4 宿主要因との相互作用
  • 5 癌化学療法薬との薬物間相互作用
  • 1. 相性について
  • 2. 投与量との関連について
  • 3. 投与タイミングについて
  • 4. 免疫賦活剤間の相互作用について
  • おわりに
  • 10 インターフェロン
  • はじめに
  • 1 インターフェロンと薬物代謝酵素系
  • 2 インターフェロンと間質性肺炎
  • 3 インターフェロン作用を増強させる薬剤
  • おわりに
  • 11 ホルモン
  • はじめに
  • 1 タモキシフェン
  • 1. 代謝と薬理動態
  • 2 プロゲステロン製剤
  • 1. 代謝と薬理動態
  • 3 ホルモン療法剤の薬物間相互作用
  • おわりに
  • Part3: 各臓器癌に対する多剤併用療法の薬物間相互作用
  • 1 頭頸部癌
  • はじめに
  • 1 頭頸部癌の科学療法
  • 1. 再発・転移症例に対する化学療法
  • 2. 薬物間相互作用
  • 3. 抗癌剤同士の薬物間相互作用
  • 4. 抗癌剤と他剤との薬物間相互作用
  • おわりに
  • 2 食道癌
  • はじめに
  • 1 食道癌の化学療法
  • 1. 単剤での治療成績
  • 2. 多剤併用療法
  • 3. 術前化学療法
  • 2 食道癌の放射線化学療法
  • 1. 術前放射線化学療法
  • 2. 根治を目的とした放射線化学療法
  • 3 新薬とその他の併用療法
  • 4 食道癌に対する放射線化学療法施行時の注意点
  • おわりに
  • 3 胃癌
  • はじめに
  • 1 胃癌の多剤併用療法
  • 1. EAP療法
  • 2. FP療法
  • 3. UFTM療法
  • 4. MTX+5-FU時間差療法(MF療法)
  • 5. FAMTX療法
  • 6. CPT-11/CDDP
  • 1 覚えておきたい薬物間相互作用
  • おわりに
  • 4 大腸癌
  • はじめに
  • 1 大腸癌の化学療法
  • 2 大腸癌化学療法のプロトコール
  • 3 治療効果
  • 4 薬物有害反応
  • 5 薬物間相互作用
  • 1. 5-FUの薬物間相互作用
  • 2. シスプラチンの薬物間相互作用
  • おわりに
  • 5 肝細胞癌
  • はじめに
  • 1 肝細胞癌の特徴と治療方針
  • 2 肝細胞癌に多用される抗癌剤と薬物間相互作用
  • 3 薬物間相互作用を利用した多剤併用療法の肝細胞癌に対する治療と成績
  • おわりに
  • 6 肺癌
  • はじめに
  • 1 肺癌の化学療法
  • 2 肺癌化学療法の代表的プロトコール・治療効果・薬物有害反応
  • 1. 非小細胞肺癌の代表的多剤併用化学療法プロトコール
  • 2. 小細胞肺癌の代表的多剤併用化学療法プロトコール
  • 3 肺癌化学療法時の薬物間相互作用
  • 1. 抗癌剤の代謝を阻害し, 薬物有害反応を増強させる薬剤
  • 2. 抗癌剤の併用順序で薬物有害反応・効果が違う場合
  • 3. 抗癌剤と抗痙攣薬
  • 4. 抗癌剤による肺毒性
  • 5. 末梢血幹細胞移植併用超大量化学療法と薬物間相互作用
  • おわりに
  • 7 乳癌
  • はじめに
  • 1 乳癌の多剤併用療法
  • 2 乳癌に対するおもな抗癌剤の作用機序
  • 1. アントラサイクリン
  • 2. シクロホスファミド
  • 3. マイトマイシンC
  • 4. ビノレルビン
  • 5. タキサン
  • 6. トポイソメラーゼ阻害薬
  • 7. フルオロウラシル
  • 3 乳癌治療に用いられるホルモン剤
  • 1. 抗エストロゲン
  • 2. アロマターゼ阻害薬
  • 3. LH-RHアゴニスト
  • 4. プロゲステロン
  • 4 ホルモン化学療法
  • 5 有害事象から考慮しなければならない薬物間相互作用
  • おわりに
  • 8 婦人生殖器癌
  • はじめに
  • 1 子宮頸癌の多剤併用療法
  • 2 卵巣癌の多剤併用療法
  • 1. 上皮性卵巣癌
  • 2. 胚細胞性卵巣腫瘍
  • 3 絨毛性疾患の多剤併用療法
  • 1. Low risk group
  • 2. Intermediate group～high risk group
  • 3. High risk group
  • おわりに
  • 9 泌尿器癌
  • はじめに
  • 1 膀胱癌の多剤併用療法
  • 2 前立腺癌の多剤併用療法
  • 3 薬物間相互作用
  • 1. 薬物間相互作用の観点からみた泌尿器癌の特徴
  • 2. 注意すべき薬物間相互作用
  • おわりに
  • 10 白血病・多発性骨髄腫
  • はじめに
  • 1 急性白血病の多剤併用療法
  • 2 急性白血病多剤併用療法における薬剤別相互作用の注意点
  • 1. シクロホスファミド
  • 2. エトポシド
  • 3. メトトレキサート
  • 4. メルカプトプリン
  • 5. アントラサイクリン系抗生物質
  • 6. ビンカアルカロイド
  • 7. シタラビン
  • 8. all-trans retinoic acid
  • 9. L-アスパラギナーゼ
  • 3 多発性骨髄腫の多剤併用療法
  • 4 多発性骨髄腫多剤併用療法における薬剤別相互作用の注意点
  • 1. メルファラン
  • 2. ラニムスチン
  • おわりに
  • 11 悪性リンパ腫
  • はじめに
  • 1 メトトレキサート
  • 2 ペントスタチン
  • 1. ビダラビンとの相互作用
  • 2. シクロホスファミド, イホスファミド
  • 3. アロプリノール
  • おわりに
  • 12 悪性黒色腫・皮膚癌(有棘細胞癌)
  • はじめに
  • 1 悪性黒色腫の多剤併用療法
  • 1. DAV療法
  • 2. DAVFeron療法
  • 3. CDV療法
  • 4. DACTam療法
  • 5. おもな薬物有害反応および薬物間相互作用
  • 2 有棘細胞癌の多剤併用療法
  • 1. CA療法
  • 2. CFP療法
  • 3. 塩酸イリノテカン療法
  • 4. おもな薬物有害反応および薬物間相互作用
  • おわりに
  • 13 悪性骨軟部腫瘍
  • はじめに
  • 1 悪性骨腫瘍の化学療法
  • 1. 骨肉腫の化学療法
  • 2. ユーイング肉腫の化学療法
  • 2 悪性軟部腫瘍の化学療法
  • 3 悪性骨軟部腫瘍に対するおもな抗癌剤の投与法と相互作用
  • 1. メトトレキサート
  • 2. シスプラチン
  • 3. ドキソルビシン
  • 4. ダクチノマイシン
  • 5. シクロホスファミド
  • 6. イホスファミド
  • 7. 5-フルオロウラシル
  • 8. ビンクリスチン
  • 9. エトポシド
  • おわりに
  • Part4: 薬物間相互作用を回避するためのソフトと八ード
  • 1 薬物間相互作用の研究
  • はじめに
  • 1 薬物間相互作用の定量的表現法
  • 2 阻害薬の門脈内濃度
  • 3 阻害薬となる薬物の肝臓内濃度
  • 4 薬物の消化管での代謝
  • 5 消化管での分泌阻害
  • 6 薬物間相互作用に関する臨床試験の実施
  • 2 薬物間相互作用に関する薬品情報
  • はじめに
  • 1 薬物間相互作用を回避するための薬品情報
  • 2 注意すべき薬物間相互作用の把握
  • 1. 薬物間相互作用の概要
  • 2. 薬物間相互作用の情報源
  • 3. 医療用医薬品添付文書
  • 3 患者への薬品情報の提供(能動的服薬指導)
  • 4 患者の薬物療法の把握(薬歴の一元管理)
  • おわりに
  • 付
  • 1 癌性疼痛コントロールにおける鎮痛薬と向精神薬の相互作用
  • はじめに
  • 1 向精神薬と鎮痛薬の相互作用
  • 1. 抗精神病薬
  • 2. 抗うつ薬
  • 3. 抗不安薬, 睡眠薬
  • 4. 抗てんかん薬
  • おわりに
  • 2 患者への日常生活指導(日本臨床腫瘍研究会編小冊子より)
  • はじめに
  • 1 日本臨床腫瘍研究会が「がんの科学療法Do it Together」を編集刊行した理由
  • 2 抗癌剤治療の説明はどうあるべきか
  • 3 抗癌剤の副作用とその防止・軽減のための患者生活指導
  • 1. 白血球減少
  • 2. 血小板減少
  • 3. 貧血
  • 4. 悪心・嘔吐
  • 5. 脱毛
  • 6. 下痢・便秘
  • 7. 性生活
  • 8. 抗癌剤治療中の精神状態
  • おわりに
  • 索引
  • 奥付

この書籍の参考文献

参考文献のリンクは、リンク先の都合等により正しく表示されない場合がありますので、あらかじめご了承下さい。

本参考文献は電子書籍掲載内容を元にしております。

Part1: 薬物間相互作用の基礎知識

P.29 掲載の参考文献
1) 千葉寛:チトクロームP-450を介した薬物相互作用. ファルマシア 31:992-996, 1995
 
2) 千葉寛:相互作用から見た薬物代謝. 日本病院薬剤師会雑誌 31:981-987, 1995
 
3) Wagner, F., Kalusche, D., Trenk, D. et al.:Drug interaction between propafenone and metoprolol. Br. J. CIin. Pharmacol. 24:213-220, 1987
 
4) Wijnands, W. J., Vree, T. B. and van Herwaarden, C. L.:The influence of quinolone derivatives on theophylline clearance. Br. J. Clin. Pharmacol. 22:677-683, 1986
PubMed
5) Upton, R. A.:Pharmacokinetic interaction between theophylline and other medication (part I, II) Clin. Pharmacokinet. 20:66-80, 135-150, 1991
 
6) Periti, P., Mazzei, T., Mini, E. et al.:Pharmacokinetic drug interactions of macrolides. Clin. Pharmacokinet. 23:106-131, 1992
PubMed
7) Zimmermann, M., Duruz, H., Guinand, O. et al.:Torsades de pointes after treatment with terfenadine and ketoconazole. Eur. Heart J. 113:1002-1003, 1992
 
8) Goss, J. E., Ramo, B. W., Blake, K. et al.:Torsades de pointes associated with astemizole (Hismanal) therapy. Arch. Intern. Med. 153:2705, 1993
PubMed
9) Murray, M.:P-450 enzymes. Clin. Pharmacofeinet. 23:132-146, 1992
 
10) Somogyi, A. and Murhead, M:Pharmacokinetic interaction of cimetidine 1987. Clin. Pharmacokinet. 12:321-366, 1987
 
11) Knodell, R. G., Browne, D. G., Gwozdz, G. P. et al.:Differential inhibition of individual human liver cytochromes P-450 by cimetidine. Gastroenterology 101:1680-691, 1991
PubMed
12) Maurice, M., Pichard, L., Daujat, M. et al. Effects of imidazole derivatives on cytochromes P-450 from human hepatocytes in primary culture. FASEB J. 6:752-758, 1992
PubMed
13) Schein, J. R.,:Cigarette smoking and clinical significant drug interactions. Ann. Pharmather. 29:1139-1148, 1995
 
14) Kivistro, K. T., Kroemer, H. K. and Eichelbaum, M.:The role of human cytochrome P-450 enzymes in the metabolism of anticancer agents:implications for drug interactions. Br. J. Clin. Pharmacol. 40:523-530, 1995
 
P.43 掲載の参考文献
1) 厚生省薬務局企画課監修:医薬品相互作用ハンドブック. 薬業時報社, 東京, 1992
 
2) 乾賢一:小腸及び腎尿細管上皮細胞膜における薬物輸送機構に関する研究. 薬学雑誌 108:921-937, 1988
 
3) 高野幹久, 乾賢一:医薬品の腎排泄機構. ファルマシア 32:400-405, 1996
 
4) 乾賢一:尿細管上皮細胞の. 薬物輸送系. BIO Clinica 11:970-973, 1996
 
5) Pritchard, J. B. and Miller, D. S.:Mechanisms mediating renal secretion of organic anions and cations. Physiol. Rev. 73:765-796, 1993
PubMed
6) Katsura, T., Takano, M., Tomita, Y. et al.:Characteristics of organic cation transporter in rat renal basolateral membrane. Biochim. Biophys. Acta 1146:197-202, 1993
PubMed
7) Saito, H., Yamamoto, M., Inui, K. et al.:Transcellular transport of organic cation across monolayers of kidney epithelial cell line LLC-PK,. Am. J. Physiol. 262:C59-C66, 1992
PubMed
8) Grundemann, D., Gorboulev, V., Gambaryan, S. et al.:Drug excretion mediated by a new prototype of polyspecific transporter. Nature 372:549-552, 1994
PubMed
9) Okuda, M., Saito, H., Urakami, Y. et al.:cDNA cloning and functional expression of a novel rat kidney organic cation transporter, OCT2. Biochem. Biophys. Res. Commun. 224:500-507, 1996
PubMed
10) Nagai, J., Takano, M., Hirozane, K. et al.:Specificity of p-amino-hippurate transport system in the OK kidney epithelial cell line. J. Pharmacol. Exp. Ther. 274:1161-1166, 1995
 
11) Jacqemin, E., Hagenbuch, B., Stieger, B. et al.:Expression cloning of a rat liver Na+-independent organic anion transporter. Proc. Natl. Acad. Sci. USA 91:133-137, 1994
PubMed
12) Saito, H., Masuda, S. and Inui, K:Cloning and functional characterization of a novel rat organic anion transporter mediating basolateral uptake of methotrexate in the kidney. J. Biol. Chem. 271:20719-20725, 1996
PubMed
13) Gottesman, M. M. and Pastan, I.:Biochemistry of multidrug resistance mediated by the multidrug transporter. Annu. Rev. Biochem. 62:385-427, 1993
PubMed
14) Tanigawara, Y., Okamura, N, Hirai, M. et al.:Transport of digoxin by human P-glycoprotein expressed in a porcine kidney epithelial cell line (LLC-PK1). J. Pharmacol. Exp. Ther. 263:840-845, 1992
 
15) Fei, Y.-J., Kanai, Y., Nussberger, S. et al.:Expression cloning of a mammalian proton-coupled oligopeptide transporter. Nature 368:563-566, 1994
PubMed
16) Saito, H., Okuda, M., Terada, T. et al.:Cloning and characterization of a rat H+/peptide cotransporter mediating absorption of B-lactam antibiotics in the intestine and kidney. J Pharmacol. Exp Ther. 275:1631-1637, 1995
 
17) Saito, H., Terada, T., Okuda, M. et al.:Molecular cloning and tissue distribution of rat peptide transporter PEPT2. Biochim. Biophys. Acta 1280:173-177, 1996
PubMed
18) Takano, M., Ohishi, Y., Okuda, M. et al.:Transport of gentamicin and fluid-phase endocytosis markers in the LLC-PK1 kidney epithelial cell line. J. Pharmacol. Exp. Ther. 268:669-674, 1994
 
19) Moestrup, S. K., Cui, S., Vorum, H. et al.:Evidence that epithelial glycoprotein 330/megalin mediates uptake of polybasic drugs. J. Clin. Invest. 96:1404-1413, 1995
PubMed
P.60 掲載の参考文献
1) Klaassen, C. D. and Watkins, III, J. B.:Mechanisms of bile formation, hepatic uptake, and biliary excretion. Pharmacol. Rev. 36:1-68, 1984
 
2) Oude Elferink, R. P. J., Meijer, D. K. F., Kuipers, F. et al.:Hepatobiliary secretion of organic compounds;molecular mechanisms of membrane transport. Biochim. Biophys. Acta 1241:21-268, 1995
 
3) Yamazaki, M., Suzuki, H. and Sugiyama, Y.:Recent advances in carrier-mediated hepatic uptake and biliary excretion of xenbiotics. Pharm. Res. 13:497-513, 1996
 
4) Joseph, S. K., Bradford, N. M. and Mcgivan, J. D.:Characteristics of the transport of alanine, serine and glutamine across the plasma membrane of isolated rat liver cells. Biochem. J. 176:827-836, 1978
PubMed
5) LeCam, A. and Freychat, P.:Neutral amlno Characterization of the A and L systems in isolated rat hepatocytes. J. Biol. Chem. 252:148-156, 1977
 
6) Goldenberg, G., Lam, H. and Begleiter, A.:Active carrier-mediated transport of melphalan by two separate amino acid transport systems in LPC-1 plasmacytoma cells in vitro. J. Biol. Chem. 254:1057-1064, 1979
PubMed
7) Arric, B. A. and Nathan, C. F.:Glutathione metabolism as a determinant of therapeutic efficacy:a review. Cancer Res. 44:4224-4232, 1984
 
8) Plagemann, P. G. W., Wohlhueter, R. M. and Woffendin, C.:Nucleoside and nucleobace transport in animal cells. Biochim. Biophys. Acta 974:405-443, 1988
 
9) Pritchard, J. B., O' connor, N., Oliver, J. M. et al.:Uptake and supply of purine compounds by the liver. Am. J. Physiol. 229:967-972, 1975
PubMed
10) Frimmer, M. and Ziegler, K.:The transport of bile acids in liver cells. Biochim. Biophys. Acta 947:75-99, 1988
PubMed
11) Hagenbuch, B., Stieger, B., Foguet, M. et al.:Functional expresstion cloning and characterization of the hepatocyte Na+/bile acid cotransport system. Proc. Natl. Acad. Sci. USA 488:10692-10633, 1991
 
12) Hagenbuch, B. and Meier, P. J.:Molecular cloning, chromosomal localization, and functional characterization of a human liver Na+/bile acid cotransport. J. Clin. Invest. 93:1326-1331, 1994
PubMed
13) Boelsterli, U. A., Zimmerli, B. and Meier, P. J.:Identification and characterization of a basolateral dicarboxylate/cholate antiport system in rat hepatocytes. Am. J. Physiol. 268:G797-G805, 1995
PubMed
14) Zimmerli, B., Valantinas, J. and Meier, P. J.:Multispecificity of Na+/dependent taurocholate uptake in basolateral (sinusoidal) rat liver plasma membrane vesicles. J. Pharm. Exp. Ther. 250:301-308, 1989
 
15) Siegler, K., Frimmer, M., Kessler, H. el al.:Modified somatostatins as inhibitors of a multispecific transport systems for bileacids and phallotoxin. Biochim. Biophys. Acta 845:86-93, 1985
 
16) Gewirtz, D., Randolph, J. K. and Goldman, I. D.:Potent bile saltand organic anion inhibition of methotrexate uptake and accumulation in the freshly isolated rat hepatocyte. Cancer Res. 40:1852-1857, 1980
 
17) Horne, D. W. and Reed, K. A.:Transport of methotrexate in basolateral membrane vesicles from rat liver. Arch. Biochem. Biophys. 298:121-128, 1992
PubMed
18) Rord, J. M. and Hait, W. N.:Pharmacology of drugs that altermultidrug resistance in cancer. Pharmacol. Rev. 42:155-199, 1990
 
19) Rohme, M, Muller, M., Leier, I. et al.:Cholestasis caused by inhibition of the adenosine triphosphate-dependent bile salt transport in rat liver. Gastroenterology 107:225-265, 1994
 
20) Jacquemin, E., Hagenbuch, B., Stieger, B. et al.:Expression cloning of a rat liver Na+-independent organic anion transporter. Proc. Natl. Acad. Sci. USA 91:133-137, 1994
PubMed
21) Steen, H. and Meijer, D. K F.:Biliary excretion of drugs and other chemicals. In:Progress in Pharmacology and Clinical Pharmacology, vol. 8/9, ed. by Siegers, C. P. and Watkins, J. B. G, Fischer Verlag, Stuttgart-New York, 1991
 
22) Mol, W. E. M., Fokkema, G. N., Weert, B. et al.:Mechanisms for the hepatic uptake of organic cations. Studies with the muscle relaxant vecuronium in isolated rat hepatocytes. J. Pharm. Exp. Ther. 244:268-275, 1988
 
23) Steen, H., Oosting, R. and Mejier, D. K. F.:Mechanisms for the uptake of cationic drugs by the liver:a study with tributylmethylammonium (TBuMA). J. Pharm. Exp. Ther. 258:537-543, 1991
 
24) 治療薬マニュアル96. 医学書院, 東京, 1996
 
25) Gatmaitan, Z. C. and Arias, I. M.:ATP-dependent transport systems in the canalicular membrane of the hepatocyte. Physiol. Rev. 75:261-275, 1995
PubMed
26) Arias, I. M., Gatmaitan, C. Z., Leveille, C. et al.:The biology ofthe bile canaliculus, 1993. Hepatology 17:318-319, 1993
 
27) Che, M., Nishida, T., Gatmaitan, Z. et al.:A nucleoside transporter is functionally linked to ectonucleotidases in rat liver canalicular membrane. J. Biol. Chem. 267:9684-9688, 1992
PubMed
28) Che, M., Ortiz, D. F. and Arias, I. M.:Primary structure and functional expression of a cDNA encoding the bile canalicular, purine-specific Na+/nucleoside cotransporter. J. Biol. Chem. 270:13596-13599, 1995
PubMed
29) Adachi, Y., Kobayashi, H., Kurumi, Y. et al.:ATP-dependent taurocholate transport by rat liver canalicular membrane vesicles. Hepatology 14:655-659, 1991
PubMed
30) Paulusma, C. C., Bosma, P. J., Zaman, J. R. et al.:Congenital jaundice in rats with a mutation in a multidrug resistance-as-sociated protein gene. Science 271:1126-1128, 1996
 
31) Gupta, E., Lestingi, T. M., Mick, R. et al.:Melabolic fate of irinotecan in humans:correlation of glucuronidation with diarrhea. Cancer Res. 54:3723-3725, 1994
PubMed
32) Lien, E. A., Anker, G., Lonning, P. E. et al.:Decreased serum concentrations of tamoxifen and its metabolites induced by aminoglutethimide. Cancer Res. 50:5851-5857, 1990
PubMed
33) Hande, K., Anthony, L, Hamilton, R. et al.:Indentification of etoposide glucuronide as major metabolite of etoposide in the rat and rabbit. Cancer Res. 48:1829-1834, 1988
 
34) Sommadossi, J.-P., Cross, D. S., Gewirtz, D. A. et al.:Evidence from rat hepatocytes of an unrecognized pathway of 5-fluorour-acil metabolism with the formation of a glucuronide derivative. Cancer Res. 45:2450-2455, 1985
 
35) Gottesman, M. M. and Pastan, I.:Biochemistry of multidrug resistance mediated by the multidrug transporter. Annu. Rev. Biochem. 62:385-427, 1993
PubMed
36) Bellamy, W. T.:P-glycoprotein and multidrug resistance. Annu. Rev. Toxicol. 36:161-183, 1996
PubMed
37) Kamimoto, Y., Gatmaitan, Y. G., Hsu, J. et al.:The function of Gp170, the multidrug resistance gene product, in rat liver canalicular membrane vesicles. J. Biol. Chem. 264:11693-11698, 1989
 
38) Watanabe, T., Miyauchi, S., Sawada, Y. et al.:Kinetic analysis of hepatobiliary transport of vincristine in perfused rat liver. J. Hepatol. 16:77-88, 1992
 
39) Bolombo, T., Zucchetti, M. and D'incalci, M.:Cyclosporin A markedly changes the distribution of doxorubicin in mice and rats. J. Pharm. Exp. Ther. 269:22-27, 1994
 
40) Smit, J. J. M., Schinkel, A. H., Elferink, R. P. J. O. et al.:Homozygous disruption of the murine mdr2 p-glycoprotein gene leads to a complete absence of phospholipid from bile and liver disease. Cell 75:451-462, 1993
 
41) Raderer, M. and Scheithauer, W.:Clincal trials of agents that reverse multidrug resistance. Cancer 72:3533-3562, 1993
 
42) Lum, B. L., Fisher, G. A., Brophy, N. A. et al.:Clinical trials of modulation of multidrug resistance. Pharmacokinetic and pharmacodynamic considerations. Cancer 72:3502-3514, 1993
PubMed
43) Ford, J. M. and Hait, W. N.:Pharmacologic circumvention of multidrug resistance. Cytotechnology 12:171-212, 1993
PubMed
44) Schuets, E. G., Schinkel, A. H., Relling, M. V. et al.:P-glyco-protein:a major determinant of rifampicin-inducible expression of cytochrome P450A in mice and humans. Proc. Natl. Acad. Sci. USA 93:4001-4005, 1996
 
P.78 掲載の参考文献
1) Lipka, E., Crison, J. R., Schug, B. S. et al.:Drug interactions in the gastrointestinal tract and their impact on drug absorption and systemic availability:a mathematic review. In:Handbook of Experimental Pharmacology, Mechanisms of Drug lnteractions, vol. 122, ed. by D'Arcy P. F., McElnay, J. C., Weling, P. G., Springer, 1996, pp.13-43
 
2) Lebsack, M. E., Nix, D., Ryeerson, B. et al.:Effect of gastric acidity on enoxacin absorption. Clin. Pharmacol. Ther. 52:252-256, 1992
 
3) Van del Meer, J. W., Keuning, J. J., Scheijgrond, H. W. et al.:The influence of gastric acidity on the bioavailability of ketoconazole. J. Antimicrob. Chemother. 6:552-554, 1980
 
4) Barr, W. H., Adir, J. and Garrettson, K.:Decrease of tetracycline absorption in man by sodium bicarbonate. Clin. Pharmacol. Ther. 12:779-784, 1971
 
5) Nimmo, J., Heading, R. C., Tothill, P. et al.:Pharmacological modification of gastric emptying:effects of propantheline and metoclopramide on paracetamol absorption. Br. Med. J. 1:587-589, 1973
PubMed
6) Manninen, V., Apajalahti, A., Melin, J. et al.:Altered absorption of digoxin in patients given propantheline and metoclopramide. Lancet 800:398-400, 1973
 
7) Levy, G. and Rao, B. K.:Enhanced intestinal absorption of rivoflavin from sodium alginate solution in man. J. Pharm. Sci. 61:279-280, 1972
 
8) Friedman, H. S. and Bonvetre, M. V.:Erythromycin-induced digoxin toxicity. Chest 82:202, 1982
 
9) Neuvonen, P. J., Gothoni, G. and Hackman, R.:Interference of iron with the absorption of tetracyclines in man. Br. Med. J. 4:532-534, 1970
 
10) Shiba, K., Saito, A., Miyahara, T. et al.:Effect of aluminum hydroxide, an antacid, on the pharmacokinetics of new quinolones in humans. 薬物動態 3:717-722, 1988
 
11) Ueno, K., Tanaka, K., Tsujimura, K. et al.:Impairment of cefdinir absorption by iron ion. Clin. Pharmacol. Ther. 54:473-475, 1993
PubMed
12) Tsuji, A. and Tamai, I.:Carrier-mediated intestinal transport of drugs. Pham. Res. 13:963-967, 1996
 
13) Garrigues, T. M., Martin, U., Peris-Ribera, J. E. et al.:Dose-dependent absorption and elimination of cefadroxil in man. Euz. J. Clin. Pharmacol. 41:179-183, 1991
 
14) 林喜代美, 崔吉道, 玉井郁巳ほか:小腸オリゴペプチド輸送担体クローンを利用したβ-ラクタム抗生物質の経口デリバリースクリーニング系開発への試み. Drug Delivery System 11:205-213, 1996
 
15) 玉井郁巳, 辻彰:ジペプチドトランスポーターと医薬品の消化管吸収. ファルマシア 31:493-497, 1995
 
16) Terao, T., Hisanaga, H., Sai, Y. et al.:Active secretion of drugs from the small intestinal epithelium in rats by P-glycoprotein functioning as an absorption barrier. J. Pharm. Pharmacol. 48:1083-1089, 1996
 
17) Hunter, J., Hirst, B. H. and Simmons, N. L.:Drug absorption limited by P-glycoprotein-mediated secretory drug transport in human intestinal epithelial Caco-2 cell layers. Pharm. Res. 10:743-749, 1993
PubMed
18) Leu, B.-L. and Huang, J.-D:Inhibition of intestinal P-glyco-protein and effects on etoposide absorption. Cancer Chemother. Pharmacol. 35:432-436, 1995
 
19) Lennernas, H. and Regardh, C. G.:Dose-dependent intestinal absorption and significant intestinal secretion (exsorption) of the beta-blocker pafenolol in the rat. Pharm. Res. 10:727-731, 1993
 
20) Murray, G. I., Barnes, T. S., Sewell, H. F. et al.:The immunocytochemical localization and distribution of cytochrome P-450 in normal human hepatic and extrahepatic tissues with a monoclonal antibody to human cytochrome P-450. Br. J. Clin. Pharmacol. 25:465-475, 1988
PubMed
21) Ducharme, M. P., Warbasse, L. H. and Edwards, D. J.:Disposition of intravenous and oral cyclosporin after administration with grapefruit juice. Clin. Pharmacol. Ther. 57:485-491, 1995
PubMed
22) Gomez, D. Y., Wacher, V. J, Tomlanovich, S. H. et al.:The effects of ketoconazole on the intestinal metabolism and biovailability of cyclosporine. Clin. Pharmacol. Ther. 58:15-19, 1995
 
23) Holtbecker, N., Fromm, M. F., Kroemer, H. K. et al.:The nifedipine-rifampicin interaction. Evidence for induction of gut wall metabolism. Drug. Metab. Disp. 24:1221-1123, 1996
 
P.91 掲載の参考文献
1) Yokogawa, K., Nakashima, E., Ishizaki, J. et al.:Relationships in the structure-tissue distribution of basic drugs in the rabbit. Pharm. Res. 7:691-696, 1990
PubMed
2) Nakashima, E. and Benet, L. Z.:General treatment of mean residence time, clearance, and volume parameters in linear mammillary models with elimination from any compartment. J. Pharmacokinet. Biopharm. 16:475-492, 1988
PubMed
3) Deguchi, Y., Koshida, R., Nakashima, E. et al.:Interindividual changes in volume of distribution of cefazolin in newborn infants and its prediction based on physiological pharmacokinetic concepts. J. Pharm. Sci. 77:674-678, 1988
PubMed
4) Yamada, K., Yasuhara, M., Yatsuzuka, A. et al.:Mechanisms of pharmacokinetic interaction between propranolol and quinidine in rats. Chem. Pharm. Bull. Tokyo 40:1876-1879, 1992
PubMed
5) Jacolot, A., Tod, M. and Petitjean, O.:Pharmacokinetic interaction between cefdinir and two angiotensin-converting enzyme inhibitors in rats. Antimicrob. Agents Chemother. 40:979-982 1996
PubMed
6) Ball, W. J., Tse, E. D., Wallick, E. T. et al.:Effect of quinidine on the digoxin receptor in vitro. J. Clin. Invest. 68:1065-1074, 1981
 
7) Robieux, I., Dorian, P., Klein, J. et al.:The effects of cardiac transplantation and cyclosporine therapy on digoxin pharmacokinetics. J. Clin. Pharmacol. 32:338-343, 1992
 
8) Baughman, G., Wiederrecht, G. J., Campbell, N. F. et al.:FKBP51, anovel T-cell-specific immunophilin capable of calcineurin inhibition. Mol. Cell. Biol. 15:4395-4402, 1995
 
9) Grem, J. L, Mulcahy, R. T., Miller, E. M. et al.:Interaction of deoxyuridine with fluorouracil and dipyridamole in a human colon cancer cell line. Biochem. Pharmacol. 38:51-59, 1989
 
10) Lombes, M., Binart, N., Delahaye, F. et al.:Differential intracellular localization of human mineralocorticosteroid receptor on binding of agonists and antagonists. Biochem. J. 302:191-197, 1994
PubMed
11) Buhrer, M., Mappes, A., Lauber, R. et al.:Dexmedetomidine decreases thiopental dose requirement and alters distribution pharmacokinetics. Anesthesiology 80:1216-1227, 1994
PubMed
12) Lourwood, D. L., Berchou, R. C. and Louis, F. R.:Diminished mephobarbital anticonvulsant action following diphenhydramine pretreatment. Res. Commun. Chem. Pathol. Pharmacol. 77:273-284, 1992
 
P.101 掲載の参考文献
1) 緊急安全性情報「抗ウイルス剤 ユースビル剤 (ソリブジン) とフルオロウラシル系薬剤との併用による重篤な血液障害について」平成5年10月
 
2) Desgranges,C., Razaka,G., De Clercq,E. et al.:Effect of (E)-5-(2-bromovinyl) uracil on the catabolism and antitumor activity of 5-fluorouracil in rats and leukemic mice. Cancer Res. 46:1094-1101, 1986
PubMed
3) 吉船伸一, 笠井浩, 長坂保則ほか:ラットにおけるYN (ソリブジン) とフルオロウラシル系薬剤との相互作用の検討. 基礎と臨床 26:2675-2688, 1994
 
4) 西本敬史, 横山信治, 坂本博彦ほか:ブロバビル (YN-72) の生体内動態 (第2報), ラットにおける代謝. 医薬品研究 21:378-389, 1990
 
5) Diasio, R. B. and Harris,B. E.:Clinical pharmacology of 5-fluorouracil. Clin.Pharmacokin. 16:215-237, 1989
 
6) 奥田晴宏, 西山貴仁, 小倉健一郎ほか:ラットにおけるソリブジンと 5-フルオロウラシル誘導体の併用経口投与による致死的毒性発現とそのメカニズム. 薬物動態10 (suppl.):S166-S169, 1995
 
7) 荻原俊男, 三上洋, 中丸光昭ほか:抗ウイルス剤YN-72 (BV-araU, ブロバビル) の臨床第一相試験. 薬理と治療18:507-523, 1990
 
8) 澤田康文:薬の飲み合わせ. 講談社ブルーバックス, 東京, 1996
 

Part2: 分類別抗癌剤の薬物間相互作用

P.115 掲載の参考文献
1) Colvin,M.:The alkylating agents. In:Pharmacologic Principles Of Cancer Treatment. (Chabner, B.A. ed.)
 
2) Struck,R.F., Alberts,D.S., Horne,K. et al.:Plasma pharmacokinetics of cyclophosphamide and its cytotoxic metabolites after intravenous versus oral administration in a randomized, crossover trial Cancer Res. 47:2723-2726, 1987
 
3) Kupari, M., Volin, L., Suokas,A. et al.:Cardiac involvement in bone marrow transplantation:serial changes ill left ventricular size, mass and performance. J.Intern.Med. 227:259-266, 1990
 
4) Gryn,J., Gordon,R., Bapat,A. et al.:Pentostatin increases the acute toxicity of high dose cyclophosphamide. Bone Marrow Transplant. 12:217-220, 1993
PubMed
5) 下山正徳, 仁井谷久暢, 木村禧代二:Cyclophosphamide及びその関連活性型物質の化学療法効果. 1. Phenobarbitalによるcyclophosphamideの活性化増強の意義と血中活性型物質の殺細胞作用. 癌と化学療法 2:877-882, 1975
Medical*Online
6) Faber,O. K., Mouridsen,H.T. and Skovsted,L.:The biotransformation of cyclophosphamide in man:influence of prednisone. Acta Pharmacol. Toxicol. 35:195-200, 1974
PubMed
7) Kuhlmann, J., Zilly,W. and Wilke, J.:Effects of cytostatic drugs on plasma level and renal excretion on beta-acetyldigoxin. Clin. Pharmacol. Ther. 30:518-527, 1981
PubMed
8) Dillman, J.B.:Safe use of succinylcholine during repeated aneshetics in patient treated with cyclophosphamide. Anesth. Analg. 66:351-353, 1987
PubMed
9) Boston Collaborative Drug Surveillance Program:Allopurinol and cytotoxic drugs. JAMA 227:1036-1040, 1974
PubMed
10) Witten, J., Frederiksen, P.L. and Mouridsen, H.T.:The pharmacokinetics of cyclophosphamide in man after treatment with allopurinol. Acta Pharmacol. Toxicol. 46:392-394, 1980
PubMed
11) Tashima, C.K.:Cyclophosphamide effect on coumarin anticoagulation. South Med. J. 72:633-634, 1979
PubMed
12) Meanwell, C.A., Blake, A.E. and Latief, T.N.:Encephalopathy associated with ifosphamide/mesna therapy. Lancet i:406-407, 1985
PubMed
13) Cantwell, B.M.J., Pooley, J. and Harris, A.L.:False-positive ketonuria during ifosphamide and mesna therapy. Eur.J. Cancer Clin. Oncol. 22:229-230, 1986
 
14) Tattersall, M. H. N, Jarman, M., Newlands, E. S. et al.:Pharmacokinetics of melphalan following oral or intravenous administration in patients with malignant disease. Eur.J. Cancer 14:507-513, 1978
 
15) Atkinson,K., Biggs,J., Concannon,A. et al.:Second marrow transplants for recurrence of hematological malignancy. Bone Marrow Transplant. 1:159-166, 1986
PubMed
16) Sviland, L, Robinson, A., Proctor, S.J. et al.:Interaction of cimetidine with oral melphalan. Cancer Chemother. Pharmacol. 20:173-175, 1987
PubMed
17) Bennett, E.J., Schmidt, G.B., Patel, K.P. et al.:Muscle relaxants, myasthenia and mustards? Anesthesiology 46:220-221, 1977
PubMed
18) Podell, L.N. and Winkler,S. S.:Busulfan lung:report of two cases and a review of the literature. Am. J. Roentgenol. 120:151-156, 1974
 
19) Grochow,L.B., Jones,R.J., Brndrett, B.R. et al.:Pharmacokinetics of busulfan:correlation with veno-occulusive disease in patients undergoing bone marrow transplantation. Cancer Chemother. Pharmacol. 25:55-61, 1989
 
20) Nelson,D.F, Diener-West, M., Horton, J. et al.:Combined modality approach to treatment of malignant gliomas-re-evaluation of RTOG 7401/ECOG 1374 with long term follow-up:a joint study of Radiation Therapy Oncology Group. NCI Monogr. 6:279-284, 1988
 
21) Loo,T.L, Housholder, G.E., Gerulath, A.H. et al.:Mechanism of action and pharmacology studies of DTIC (NSC-45388). Cancer Treat. Rep. 60:149-157, 1976
PubMed
22) Chabot,G G., Flaherty,L.E., Valdivieso, M. et al.:Alteration of dacarbazine pharmacokinetics after interleukin-2 administration in melanoma patients. Cancer Chemother. Pharmacol. 27:157-160, 1990
PubMed
23) Spivack,S.D.:Procarbazine. Ann. Intern. Med. 81:795-800, 1974
PubMed
24) Anonymous:Foods interacting with MAO inhibitors. Med. Lett. 31:11-12, 1989
 
P.126 掲載の参考文献
1) Dam on, L..E, Mass, R. and Linker, C.A.:The association between highdose cytarabine neurotoxicity and renal insufficiency. J. Clin. Oncol. 7:1563-1568, 1989
 
2) Bhalla, K., Swerdlow, P. and Grant, S.:Effects of thymidine and hydroxyurea on the metabolism and cytotoxicity of 1-B-D arabinofuranosylcytosine in highly resistant human leukemia cells. Blood 78:2937-2944, 1991
 
3) Grant, S.:Biochemical modulation of cytosine arabinoside. Pharmacol. Ther. 48:29-44, 1990
PubMed
4) Ehnninger, G., Proksch, B., Wanner, T. et al.:Intracellular cytosine arabinoside triphosphate formation in leukemia blast cells is inhibited by etoposide and teniposide. Leukemia 6:582-587, 1992
 
5) Liliemark, J., Knochenhauer, E., Gruber, A. et al.:On the interaction between cytosine arabinoside and etoposide in vivo and in vitro. Eur. J. Haematol. 50:22-26, 1993
PubMed
6) Reuter, C., der Landwehr, U. A., Schleyer, E. et al.:Modulation of intracellular metabolism of cytosine arabinoside in acute myeloid leukemia by Granulocyte-Macrophage colony-stimulating factor. Leukemia 8:217-225, 1994
 
7) Aneme, G.N., Prall, E., Marks, V. et al.:Prolongation and enhancement of serum methotrexate concentration by probenecid. Br. Med. J. 1:1097, 1978
 
8) Singh, R.R., Malaviya, A., Pandey, J.N. et al.:Fatal interaction between methotrexate and non steroidal anti inflammatory drugs. Lancet i:8480-8483, 1986
 
9) Jeurissen, M.E., Boerbooms, A.M. and van der Putte, L.B.:Pancytopenia and methotrexate with trimethoprim-sulpamethoxazole. Ann. lntern. Med. 111:261, 1989
 
10) Berns, A., Rubenfeld, S. and Rymzo, W. T.:Hazard of combining allopurinol with thiopurine. N. Eng. J. Med. 286:763-765, 1972
 
11) Dicker, A.P., Woltham, M.C., Volkenandt, M. et al.:Methotrexate resistance in an in vivo mouse tumor due to a non-active-site dihydrofolate reductase mutation. Proc. Natl. Acad. Sci. USA 90:11797-11801, 1993
 
12) Curt, C.A., Joliet, J., Camay, D.N. et al.:Determinants of the sensitivity of human small-cell lung cancer cell lines to methotrexate. J. Clin. Invest. 76:1323-1327, 1985
 
13) Grever, M. et al.:Randomized comparison of pentostatin versus interferon alfa-2a in previously untreated patients with hairy cell leukemia:an intergroup study. J. Clin. Oncol. 13:974, 1995
PubMed
14) Cheson, B.D., Vena, D.A., Sorensen, J.M. et al.:Current status of US. clinical trials in chronic lymphocytic leukemia. Leuk. Lymphoma (suppl.):119-122, 1991
 
15) Gryn, J., Gordon, R, Bapat, N. et al. Pentostatin increase the acute toxicity of high dose cyclophosphamide. Bone Marrow Transplant. 12:217-220, 1993
 
16) Hershfield, M.S.:Apparent suicide inactivation of human lymphoblast S-adenosyl-homocysteine hydrolase by 2'-deoxyadenosine and adenine arabinoside. J. Biol. Chem. 254:22-25, 1979
PubMed
17) Steinmetz, J.C., DeConti, R., Ginsburg, R. et al.:Hypersensitivity vasculitis associated with 2-geoxycoformycin and allopurinol therapy. Am. J. Med. 86:499-500, 1989
 
P.148 掲載の参考文献
1) Akazawa, S., Kumai, R, Yoshida, K. et al.:The cytotoxicity of 5-fluorouracil is due to its incorporation into RNA not its inhibition of thymidylate synthase as evidenced by the use of a mouse cell mutant deficient in thymidylate synthase. Jpn. J. Cancer Res. (Gann) 77:620-624, 1986
 
2) Ayusawa, D., Arai, H., Wataya, Y. et al.:A specialized form of chromosomal DNA degradation induced by thymidylate stress in mouse FM3A cells. Mutation Res. 200:221-230, 1988
PubMed
3) Akazawa, S. and Yoshida, K.:Leucovorin enhancement of the effects of the fluoropyrimidines on chromosomal DNA degradation. Cancer Chemotherapy:Challenges for the Future 5:113-117, 1990
 
4) 有岡仁, 西條長宏:Biochemical Modulationの考え方. 癌治療とBio-modulation, 漆崎一朗編, 医薬ジャーナル社, 大阪, 1995, pp.93-99
 
5) Cadman, E., Heimer, R. and Davis, L.:Enhanced 5-fluorouracil nucleotide formation after methotrexate administration:explanation for drug synergism. Science 205:1135-1137, 1979
PubMed
6) 涌井昭:併用投与. 癌と化学療法 12:806-814, 1985
Medical*Online
7) Fernandes, D. J. and Bertino, J. R.:5-fluorouracil-methotrexate synergy:enhancement of 5-fluorodeoxyuridylate binding to thymidylate synthase by dihydropteroglpolyglutamates. Proc. Natl. Acad. Sci. USA 77:5663-5667, 1980
PubMed
8) 佐々木常雄:5-FU/Leucovorin療法. 癌治療とBiomodulation, 漆崎一朗編, 医薬ジャーナル社, 大阪, 1995, pp.111-118
 
9) Santi, D. V. et al.:Inhibition of thymidylate synthetase. In:Antimetabolites in biochemistry, Biology and Medicine, Pergamon Press, 1978, pp.43-53
 
10) Evans, R. M., Laskin, J. D. and Hakala, M. T.:Effect of excess folates and doxyinosine on the activity and site of action of 5-fluorouracil. Cancer Res. 41:3288-3295, 1981
PubMed
11) Honghton, J. A., Schmidt, C. and Houghton, P. J.:The effect of derivatives of folinic acid on the fluorodeoxy uridylate thymidylate synthase covalent complex in human colon xenografts Eur. J. Cancer Clin. Oncol. 18:47-354, 1982
 
12) 赤沢修吾, 大和明子:大腸癌に対するCisplatin (CDDP)/5-fluorouracil (5-FU) 併用療法-投与方法の考え方と臨床応用の実際-. 癌と化学療法 23:1770-1779, 1996
Medical*Online
13) Scanlon, K. J., Newman, E. M., Lu, Y. et al.:Biochemical basis for cisplatin and 5-fluorouracil synergism in human ovarian carcinorna cells. Proc. Natl. Acad. Sci. USA 83:8923-8925, 1986
 
14) 江崎泰斗, 中野修治:5-FU/Cisplatin療法. 癌治療と Biomodulation, 漆崎一朗編, 医薬ジャーナル社, 大阪, 1995, pp. 119-126
 
15) 赤沢修吾, 熊井良司, 清水喜美子ほか:ThymidineおよびN-phophoacetyl-L-aspartateによる5-FUのBiochemical Modulation-特に5-FUのRNA取り込みと殺細胞効果との関係について-. 癌と化学療法13 (PART. I):990-995, 1986
 
16) Collins, K. D., and Stark, G. R.:Aspartate transcarbamylase:interaction with the transition state analogue N-(phosphoacetyl)-L-aspartate. J. Biol. Chem. 246:6599-6605, 1971
 
17) 白坂哲彦:オキソン酸による5-FUの副作用防止とその応用. 太田和雄監修, 塚越茂ほか編, Biomodulation-癌薬物療法の新たな展開-, 先端医学社, 東京, 1994, pp. 69-78
 
18) 稲葉実:5-FUの効果増強. 癌と化学療法 15:380-391, 1988
Medical*Online
19) 菅原和信:チオプリン類 (アザチオプリンなど) および5-フルオロウラシルの分解阻害による血液障害. 治療 76:2357-2364, 1994
Medical*Online
20) 栗原稔:UFT (UFT+CDDPを含む). BIOCHEMICAL MODULATIONの基礎と臨床, 金丸龍之介, 小西敏郎編, 医学書院, 東京, 1995, pp.50-55
 
21) Tatsumi, K., Yamauchi, T., Kiyono, K. et al:3-cyano-2, 6-dihydroxypyridine (CNDP), a new potent inhibitor of dihydrouracil dehydrogenase. J. Biochem. 114:912-918, 1993
PubMed
22) Baker, S.D., Khor, S.P., Adjei, A.A. et al.:Pharmacokinetic, oral bioavailability, and safety study of fluorouracil in patients treated with 776C85, an inactivator of dihydropyrimidine dehydrogenase. J. Clin. Oncol. 14:3085-3096, 1996
PubMed
23) 赤沢修吾, . 寺師薫, . 大和明子ほか;IFN-α/5-FU併用療法. Biotherapy 10:589-597, 1996
Medical*Online
24) Chu, E, Zinn, S., Boarman, D. et al.:Interaction of γ interferon and 5-fluorouracil in the H630 human colon carcinoma cell line. Cancer Res. 50:5834-5840, 1990
 
25) 赤沢修吾, 吉田清一:Interferon-αによる5-FUのbiochemical modulation-Interferon-αと 5-FUの投与方法の検討. 消化器癌 2:83-87, 1992
 
26) 赤沢修吾:インターフェロンによる5-FUのbiochemical modulation. 医学のあゆみ 164:305-309, 1993
Medical*Online
27) Moertel, C. G., Fleming, T. R., MacDonald, J. S. et al.:Levamisole and fluorouracil for adjuvant therapy of resected colon carcinoma. N. Engl. J. Med. 322:352-358, 1990
PubMed
28) 前原喜彦, 犬塚貞明, 杉町圭蔵:Dipyridamoleによる抗癌剤効果増強. 医学のあゆみ164:273-276, 1993
 
29) Harvey, V. J., Slevin, M. L., Dilloway, M. R. et al.:The influence of cimetidine on the pharmacokinetics of 5-fluorouracil. Br. J. Clin. Pharmacol. 18:421-430, 1984
PubMed
30) Bardakji, Z., Jolivet, J., Langelier, Y. et al.:5-fluorouracil-metronidazole combination therapy in metastatic colorectal cancer. Cancer Chemother. Pharmacol. 18:140-144, 1986
PubMed
P.160 掲載の参考文献
1) 北田光一:薬物相互作用総論. Prog. Med. 16:2277-2280, 1996
Medical*Online
2) 仲川義人編:医薬品相互作用. 医薬ジャーナル社, 大阪, 1994, pp.488-491
 
3) 大森栄:代謝過程における薬物相互作用. Prog. Med. 16:2290-2295, 1996
Medical*Online
4) Loadman, P.M. and Bibby, M.:Pharmacokinetic drug interactions with anti-cancer drugs. Clin. Pharmacokinet. 26:486-500, 1994
 
5) 南博信:抗癌剤と他剤との薬物相互作用. Prog. Med. 16:2349-2354, 1996
Medical*Online
6) 塚越茂:薬動力学からみた抗がん剤の副作用の発現機序. がん化学療法の副作用対策, 吉田清一監修, 赤沢修吾, 桜井雅温編, 先端医学社, 東京, 1992, pp. 103-110
 
7) Quesnel, B., Kantarjian, H., Pedersen, J. et al.:Therapy-related acute myeloid leukemia with t(8;21) inv(16), and t(8;16):a report on 25 cases and review of the literature. J. Clin. Oncol. 11:2370-2379, 1993
 
8) 寺崎哲也:排泄過程における薬物相互作用の速度論と細胞膜透過機構. Prog. Med. 16:2296-2302, 1996
Medical*Online
9) Damiani, D., Michieli, M, Michelutti, A. et al.:D-verapamil downmodulate P170-associated resistance to doxorubicin, daunorubicin and idarubicin. Anti-Cancer Drugs 4:173-180, 1993
PubMed
10) 近藤元治, 内藤裕二, 吉川敏一:抗がん剤の副作用とフリーラジカル. がん化学療法の副作用対策, 吉田清一監修, 赤沢修吾, 桜井雅温編, 先端医学社, 東京, 1992, pp. 111-119
 
11) 酒井洋:心筋障害とその対策. がん化学療法の副作用対策, 吉田清一監修, 赤沢修吾, 桜井雅温編, 先端医学社, 東京, 1992, pp. 288-295
 
12) Watanabe, N., Okamoto, T., Tsujii, N. et al.:Reversal of tumor necrosis factor resistance in tumor cells by adriamycin via suppression of intracellular resistance factors. Jpn. J. Cancer Res. 86:395-399, 1995
 
13) Berman, E., Heller, G., Santorsa, J. et al.:Results of a randomized trial comparing idarubicin and cytosine arabinoside with daunorubicin and cytosine arabinoside in adult patients with newly diagnosed acute myelogeneous leukemia. Blood 77:1666-1674, 1991
PubMed
14) 伊藤邦彦, 米田修一:肺障害とその対策. がん化学療法の副作用対策, 吉田清一監修, 赤沢修吾, 桜井雅温編, 先端医学社, 東京, 1992, pp.296-305
 
P.174 掲載の参考文献
1) Rahmani, R. and Zhou, X.:Pharmacokinetics and metabolism of vinca alkaloids. Cancer Surv. 17:269-281, 1993
 
2) Medical Oncology. 2nd edition.:ed. by Calabresi, P. and Schein, P. S. MacGraw-Hill, NewYork, 1993
 
3) Devita, V. T., Hellman, S. and Rosenberg, S. A.:Cancer. Principal & Practice Of Oncology. 5th edition. Lippincott-Raven, 1997
 
4) 有吉寛, 西條長宏, 福岡正博, 佐々木康綱, 渡部亨編:臨床腫瘍学. 日本臨床腫瘍学会編, 1996
 
5) Leveque, D. and Jehl, F.:Clinical pharmacokinetics of vinorel-bine. Clin. Pharmacokinet. 31:184-197, 1996
 
6) Albert, B., Bray, D., Lewis, J. et al.:III細胞内部の構築third edition:16. 細胞骨格:Molecular biology of the cell, 1995, pp.803-815
 
7) Jordan, M. A., Thrower, D. and Wilson, L.:Mechanism of inhibition of cell proliferation by vinca alkaloids. Cancei Res. 51:2212-2222, 1991
 
8) Jordan, M. A., Thrower, D and Wilson. L.:Effects of vinblastine. podophyllotoxin and nocodazole on mitotic spindles. Implications for the role of microtubule dynamics in mitosis. J. Cell Sci. 102:401-416, 1992
 
9) Johnson, S. A., Harper, P., Hortobagyi, G. N. et al.:Vinorelbine:an overview. Cancer Treat. Rev. 22:127-142, 1996
PubMed
10) Binet, S., Fellous, A., Lataste, H. et al.:In situ analysis of the action of Navelbine R on various types of microtubules using immunofluorescence. Semin. Oncol. 16 (suppl. 4):5-8, 1989
 
11) Fellous, A., Ohayon, R. and Vacassin, T.:Biochemical effects of Navelbine on tubulin and associated proteins. Semin. Oncol. 16 (suppl. 4):9-14, 1989
 
12) Cros, S., Wright, M., Morimoto, M. et al.:Experimental antitumour activity of Navelbine (NVB) in a human non-small cell lung cancer (NSCLC) line. Proc. Am. Ass. Cancer. Res. 36:A3637, 1989
 
13) Owellen, R. J. and Hartke, C. A.:The pharmacokinetics of 4-acetyl tritium vinblastine in two patients. Cancer Res. 35:975-980, 1975
PubMed
14) Bender, R. A., Castle, M. C., Margeileth, D. A. et al.:The pharmacokinetics[3H]-vincristine in man. Clin. Pharmacol. Ther. 22:430-438, 1977
 
15) Marquet, P., Lachatre, G., Debord, J. et al.:Pharmacokinetics of vinorelbine in man. Eur. J. Clin. Pharmacol. 42:545-547, 1992
PubMed
16) Dominique, L. and Francois, J.:Clinical Pharmacokinetics of vinorelbine. Clin. Pharmacokinet. 31:184-197, 1996
 
17) Urien, S., Bree, F, Breillout, F. et al.:Vinorelbine high-affinity binding to human platelets and lymphocytes:distribution in human blood. Cancer Chemother. Pharmacol. 32:231-234, 1993
PubMed
18) Leveque, D., Quoix, E, Dumount, P. et al.:Pulmonary distribution of vinorelbine in patients with non-small-cell lung cancer. Cancer Chemother. Pharmacol. 33:176-178, 1993
 
19) Zhou, X. J., Bore, R, Monjanel, S. et al.:Pharmacokinetics of navelbine after oral administration in cancer patients. Cancer Chemother. Pharmacol. 29:66-70, 1991
 
20) Zhou, X. J., Zhou-Pan, X. R, Favre, R. et al.:Relative bioavailability of two oral formulations of navelbine in cancer patients. . Biopharm. Drug Dispos. 15:577-586, 1994
PubMed
21) Rowinsky, E. K., Noe, D. A., Trump, D. L. et al.:Pharmacokinetic, bioavailability and feasibility study of vinorelbine in patients with solid tumors. J. Chin. Oncol. 12:1754-1763, 1994
 
22) Lucas, S. Rowinsky, E., Wargin, W. et al.:Results of a study of the effect of food on the bioavailability (BA) and pharmacokinetics (PK) of navelbine R (NVB) liquid-filled soft gelatincapsules (abstract). Proc. Am. Soc. Clin. Oncol. 12:160, 1993
 
23) Vokes, E. E., Rosenberg, R. K., Jahanzeb, M. et al.:Multicenter phase II study of weekly oral vinorelbine for stage IV non-small cell lung cancer. J. Clin. Oncol. 13:637-644, 1995
PubMed
24) Winer, E. P., Chu, L. and Specer, D. V.:Oral vinorelbine (naberbine) in the treatment of advaned breast cancer. Semin. Oncol. 22 (Suppl. 5):72-79, 1995
 
25) Zhou-Pan, X. R., Seree, E, Zhou, X. J. et al.:Involvement of human liver cytochrome P 450 3 A in vinblastine metabolism drug interactions. Cancer Res. 53:5121-5126, 1993
PubMed
26) Zhou, X. J., Zhou-Pan, X. R, Gauthier, T. et al.:Human liver microsomal cytochrome P 450 3 A isozymes mediated vindesine biotransformation. Biochem. Pharmacol. 45:853-861, 1993
PubMed
27) Mathe, G. and Reizenstein, P.:Phase I pharmacologic study of a new vinca alkaloid:navelbine. Cancer Lett. 27:285-293, 1985
PubMed
28) Furuse, K., Niitani, H., Wakui, A. et al.:Phase I study of vinorelbine (navelbine) by single or intermittent administration. Invest. New Drugs 7:456, A31, 1989
 
29) Khayat, D., Covelli, A., Variol, P. et al.:Phase I and pharmacologic study of intravenous vinorelbine in patients with solid tumours. Proc. Am. Soc. Clin Oncol. 14:A1518,1995
 
30) Depierre, A., Lemarie, E, Dabouis, G. et al.:A phase II study of navelbine in the treatment of non-small cell lung cancer. Am. J. Oncol. 14:115-119, 1991
 
31) Furuse, K., Kubota, K., kawahara, M. et al.:A phase II study of vinorelbine, a new derivative of vinca alkaloid, for previously untreated advanced non-small cell lung cancer. Lung Cancer 11:385-391, 1994
PubMed
32) Crivellari, D., Veronesi, A., Sacco, C. et al.:Phase II study of vinorelbine (V) in 50 patients (pts) with non-small cell lung cancer. Proc. Am. Soc. Clin. Oncol. 13:A1192, 1994
 
33) Pronzata, P., Landucci, M., Vaira, F. et al.:Failure of vinorelbine to produce responses in pre-treated non-small cell lung cancer patients. Anticancer Res. 14:1413-1415, 1994
 
34) Crawford, J., O'Rourke, M., Schiller, J. H. et al.:Randomized trial of vinorelbine compared with fluorouracil plus leucovorin in patiets with stage IV non-small cell lung cancer. J. Clin. Oncol.
 
35) Depierre, A., Chastang, C., Qouix, E. et al.:Vinorelbine versus vinorelbine plus cisplatin in advanced non-small cell lung cancer:arandomized trial. Ann. Oncol. 5:37-42, 1994
 
36) Le Chevalier, T., Brisgand, D., Douillard, J. Y. et al.:Randomized study of vinorelbine and cisplatin versus vindesine and cisplatin versus vinorelbine alone in advanced non-small cell lung cancer:results of a European multicentre trial including 612 patients. J. Clin. Oncol. 12:360-367, 1994
PubMed
37) Smith, T. J., Hillner, B. E., Neighbors, D. M. et al.:Economic evaluation of a randomized clincal trial comparing vinorelbine, vinorelbine plus cisplatin and vindesine plus cisplatin for non-small cell lung cancer. J. Clin. Oncol. 13:2166-2173, 1995
 
38) Gebbia, V., Caruso, M., Valenza, R. et al.:Vinorelbine plus cisplatin for the treatment of stage III B and IV non-small cell lung carcinoma. Anticancer Res. 14:1247-1249, 1994
 
39) Viallet, J., Ayoub, J., Rousseau, P. et al.:Vinorelbine (navelbine) in the adjuvant and neo-adjuvant treatment of non-small cell lung cancer. Sem. Oncol. 21(suppl. 10):64-72, 1994
 
40) Edelstein, M. P., Wolfe, L. A. and Duch, D. S.:Potentiation of radiotherapy by navelbineR (NVB) in a human non-small cell lung cancer (NSCLC) line. Proc. Am. Ass. Cancer. Res. 36:A3637, 1995
 
41) Viallet, J., Rousseau, P., Souhama, L. et al.:A completed phase I/II trial of neoadjuvant chemotherapy (CT) with cisplatin and vinorelbine followed by accelerated thoracic irradiation (TRT) in operable NSCLC. Proc. 8th. Eur. Conf. Clin. Oncol; E. J. Cancer 31A (suppl. 5):A1083, 1995
 
42) Masotti, A., Borzellino, G., Zannini, G. et al.:Efficancy and toxicity of vinorelbine-carboplatin combination in the treatment of advanced adenocarcinoma or large cell carcinoma of the lung. Tumori 81:112-116, 1995
PubMed
43) Crawford, J. and O'Rourke, M. A.:Vinorelbine (navelbine)/car-boplatin combination therapy:dose intensification with granulocyte colony-stimulating factor. Semin. Oncol. 21 (suppl. 10):73-78, 1994
 
44) Baldini, E., Tibaldi, C., Chella, A. et al.:Combination chemotherapy with vinorelbine, ifosfalnide and cisplatin:a phase II study in stage III B/IV non-small cell lung cancer. Semin. Oncol. 21 (suppl. 4):12-15, 1994
 
45) Souquet, P. J., Fournel, P., Bohas, C. H. et al.:A phase II trial of cisplatin (CDDP), ifosfamide (IFM) and increasing dosage of vinorelbine (NVB) (NIP) in non-resectable non-small cell lung cancer (NSCLC). Proc. Eur. Soc. Med. Oncol; Ann, Oncol. 5 (suppl8):A759, 1994
 
46) Canobbio, L, Boccardo, F, Pastorino, G. et al.:Phase II study of navelbine in advanced breast cancer. Semin. Oncol. 16 (suppl. 4):33-36, 1989
 
47) Garcia-Conde, J., Lunch, A., Martin, M. et al.:Phase II trial of weekly IV vinorelbine in first-line advanced breast cancer chemotherapy. Ann. Oncol. 5:854-857, 1994
 
48) Bruno, S., Puerto, L, Mickiewicz, E. et al.:Phase II trial of weekly IV vinorelbine as a single agent in first-line advanced breast cancer. The Latin-American experience. Am. J. Clin. Oncol. 18:392-396, 1995
 
49) Romero, A., Rabinovich, M. G., Vallejo, C. T. et al.:Vinorelbine as first-line chemotherapy for metastatic breast carcinoma. J. Clin. Oncol. 12:336-341, 1994
PubMed
50) Twelves, C. J., Dobbs, N. A., Curnow, A. et al.:A phase II multicenter UK study of vinorelbine in advanced breast cancer. Br. J. Cancer. 70:990-993, 1994
PubMed
51) Wedber, B. L., Vorgel, C., Jones, S. et al.:Intravenous vinorel-bine as first-line and second-line therapy in advanced breast cancer. J. Clin. Oncol. 13:2722-2730, 1995
 
52) Jones, S., Winer, E., Vogel, C. et al.:Randomized comparison of vinorelbine and melphalan in anthracycline-refractory advanced breast cancer. J. Clin. Oncol. 13:2567-2574, 1995
PubMed
53) Spielmann, M., Dorval, T., Turpin, F. et al.:Phase II trial of vinorelbine/doxorubicin as first line therapy of advanced breast cancer. J. Clin. Oncol. 12:1764-1770, 1994
PubMed
54) Blajman, C., Balbiani, L, Block, J. et al.:Navelbine(N) and adriamycin(A) versus FAC in advanced breast cancer. Proc. Am. Soc. Clin. Oncol. 12:92, 1993
 
55) Froundarakis, M., Catimel, G., Guastella, J.P. et al.:Phase II study of navelbine and 5-fluorouracil as second line chemotherapy in metastatic breast cancer. Proc. Eur. Soc. Med. Oncol. Abstract. 343, Ann. Oncol. 3 (suppl. 4):88, 1992
 
56) Dieras, V., Pierga, J. Y., Extra, J. M. et al.:Results of a combination of navelbine and fluorouracil in advanced breast cancer with agroup sequential design. Proc. Eur. Soc. Med. Onc. Abstract. 178, Ann. Oncol. 3 (suppl. 4):46, 1992
 
57) Chadjaa, M., Izzo, J., May-Levin, F. et al.:Preliminary data on 4'epiadriamycin, vinorelbine:a new active combination in advanced breast cancer. Proc. Am. Soc. Clin. Oncol. 12:A153, 1993
 
58) Van, Praagh, I., Martineau, N., Cure, H. et al.:Efficacy of a chemotherapy regimen combining vinorelbine, epirubicine and methotrexate (VEM) in locally advanced and metastatic breast cancer. . Proc. Am. Soc. Clin. Oncol. 12:95, A180, 1993
 
59) Van, Praagh. I., Leduc, B., Feillel, V. et al.:Neoadjuvant VEM chemotherapy regimen for operable breast cancer:result of a cooperative study on 69 patients. Proc. Am. Soc. Clin. Oncol. 14:A242, 1995
 
60) Chollet, P. H., Charrier, S., Brain, E. et al.:Neo-adjuvant chemotherapy in breast cancer. High pathological response rate induced by intensive anthracycline-based regimen. Proc. Am. Soc. Clin. Oncol. 14:130, A218, 1995
 
61) Ferrero, J. M., Wendling, J. L, Hoch, M. et al.:Mitoxantrone-vinorelbine as first line therapy in metastatic breast cancer. Proc. Am. Soc. Clin. Oncol. 12:108, A234, 1993
 
62) Kayitalire, L, Spielmann, M., Brain, E. et al.:Salvage chemotherapy (CT) with combination of mitoxantrone (MTS) and vinorelbine (VRB) in resistant to anthracyclines advanced breast cancer (ABC). Proc. Am. Soc. Clin. Oncol. 12:90, A161, 1993
 
63) Ibrahim, N, K., Hortobagyi, G. N, Valero, V. et al.:Phase I study of vinorelbine (NVB;NaverbineR) and paclitaxel (PTX; TaxoIR) by simultaneous (Sim) 3hour(h) infusion (inf) with G-CSF support, for untreated metastatic breast cancer (MBC). Proc. Am. Assoc. Cancer. Res. 36:A1443, 1995
 
64) Fumoleau, P., Delecroix, V., Gentin, M. et al.:Docetaxel (D) in combination with vinorelbine (V) as first-line CT in pts with MBC:phase I dose finding study. Proc. Eur. Conf. Clin. Oncol; Eur. J. Cancer. 31A (suppl. 5):A1083, 1995
 
65) Fabi, A., Tonachella, R, Savarese, A. et al.:A phase II trial of vinorelbine and thiotepa in metastatic breast cancer. Ann. Oncol. 6:187-189, 1995
PubMed
66) Geoge, M. J., Heron, J. F, Kerbrat, P. et al.:Navelbine in advanced ovarian epithelial cancer:a study of the French Oncology Centers. Semin. Oncol. 16 (suppl. 4):30-32, 1989
 
67) Devizzi, L, Santoro, A., Bonfante, V. et al.:Vinorelbine:an active drug for the management of patients with heavily pre-treated Hodgkin's disease. Ann. Oncol. 5:817-820, 1994
 
68) Ferme, C., Bastion, Y., Lepage, E. et al.:The MINE regimen as intensive salvage chemotherapy for relapsed and refractory Hodgkin's disease. Ann. Oncol. 6:543-549, 1995
PubMed
P.191 掲載の参考文献
1) Gupta, E., Lestingi, T.M., Mick, R. et al.:Metabolic fate of irinotecan in humans:Correlation of glucuronidation with diarrhea. Cancer Res. 54:3724-3725, 1995
 
2) Gupta, E, Safa, A., Wang, X. et al.:Pharmacokinetic modulation of irinotecan and metabolites by cyclosporin A. Cancer Res. 56:1309-1314, 1996
PubMed
3) Saltz, L, Kanowitz, J, , Kemeny, N. et al.:Phase I clinical and pharmacokinetic study of irinotecan, fluorouracil, leucovorin in patients with advanced solid tumors. J. Clin. Oncol. 14:2959-2967, 1996
PubMed
4) Fukuoka, M., Niitani, H., Suzuki, A. et al.:A phase II study of CPT-11, a new derivative of camptothecine, for previously untreated non-small cell lung cancer. J. Clin. Oncol. 10:16-20, 1992
 
5) Masuda, N., Fukuoka, M., Kusunoki, Y. et al.:CPT-11:a new derivative of camptothecine for the treatment of refractory or relapsed small-cell lung cancer. J. Clin. Oncol. 10:1225-1229, 1992
PubMed
6) Marchesin, R., Colombo, A., Caserin, C. et al.:Interaction of ionizing radiation with topotecan in two human tumor cell lines. lnt. J. Cancer. 66:342-346, 1996
 
7) Slevin, M. L, Clark, P. I., Joel, S. P. et al.:A randomized trial to evaluate the effect of schedule on the activity of etoposide in small-cell lung cancer. J. Clin. Oncol. 7:1333-1340, 1989
PubMed
8) Rowinsky, E.K., Gilbert, M.R, MoGuire, W. P. et al.:Sequences of taxol and cisplatin:a phase I study and pharmacologic study. J. Clin. Oncol. 9:1692-1703, 1991
 
P.200 掲載の参考文献
1) 江崎泰斗, 中野修治:5-FU/Cisplatin療法. 癌治療と Biomodula-tions, 漆崎一朗編,医薬ジャーナル社, 大阪, 1994, pp. 119-126
 
2) Tsuchiya, S., Minato, K., Nakano, H. et al.:A phase I study of 72-hour continuous infusion consisting of cisplatin and 5-fluorouracil for treatment of non-small cell lung cancer. Oncology 52:246-250, 1995
 
3) Lynch, T.J.J r., Kalish, L.A., Kass, F et al.:Continuous-infusion cisplatin, 5-fluorouracil, and leucovorin for advanced non-small cell lung cancer. Cancer 73:1171-1176, 1994
 
4) Bedini, A. V., Tavecchio, L., Lequaglie, C. et al.:Ambulatory low-toxicity chemotherapy in non-small-cell lung carcinoma by continuous 28-day infusion of alternating cisplatin and 5-fluorouracil. Ann. Oncol. 6:838-840, 1995
PubMed
5) Ichinose, Y., Takanashi, N., Yano, T. et al.:A phase I trial of oral tegafur and uracil plus cisplatin in patients with inoperable non-small cell lung cancer. Cancer 75:2677-2680, 1995
 
6) Gemma, A., Kudoh, S., Niitani, H. et al.:Pilot trial of a combination comprising of consecutive oral administration of UFT, and two-divided administration or CDDP in non-small cell lung cancer. Anticancer Res. 15:2691-2696, 1995
PubMed
7) Linch, T. J. Jr., Clark, J. R., Kalish, L.A. et al.:Continuous-infusion cisplatin, 5-fluorouracil, and bolus methotrexate in the treatment of advanced non-small cell lung cancer. Cancer 70:1880-1885, 1992
 
8) Castello, G, , Lerza, R., Mencoboni, M. et al.:Cisplatin. 5-fluorouracil and alpha interferon in non small cell lung carcinoma:a toxicity study. Anticancer Res. 14 (2B):621-635, 1994
PubMed
9) Langer, C. J., Curran, W. J. Jr., Kller, S. M. et al.:Report of phase I trial of concurrent chemoradiotherapy with radical thoracic irradiation (60Gy), infusional fluorouracil, bolus cisplatin and etoposide for clinical stage IB and bulky IA non-small cell lung cancer. Int. J. Radiat. Oncol. Biol. Phys. 26:469-478, 1993
 
10) Bolla, M., Nagy-Mignotte, H., Moro, D. et al.:Combination of 5-FU cis-platinum and hypofractionated irradiation followed by split-course radiotherapy in 47 patients with unresectable non small cell lung cancer. Radiother. Oncol. 25:186-191, 1992
PubMed
11) Morere, J. F., Duran, A., Tcherakian, F. et al.:Cisplatin-5-fluorouracil in small cell lung cancer. A phase study in 109 patients. Lung Cancer 11:275-281, 1994
PubMed
12) 小林国彦:フッ化ピリミジンと白金化合物の効果的投与法. 癌と化学療法 23:1747-1756, 1996
 
13) 藤井正人, 大野芳裕, 神崎仁:頭頸部癌に対するCDDPと5-FU併用療法におけるCDDP単回投与と5分割投与の比較. 日癌治30:183-1839, 1995
 
14) De Andres, L, Brunet, J, Lopez-Pousa, A. et al.:Randomized trial of neoadjuvant cisplatin and fluorouracil versus carboplatin and fluorouracil in patients with stage IV-MO head and neck cancer. J. Clin. Oncol. 13:1493-1500, 1995
PubMed
15) Reddy, S. P., Lad, T., Mullane, M. et al.:Radiotherapy alone compared with radiotherapy and chemotherapy in patients with squamous cell carcinoma of the esophagus. Am. J. Clin. Oncol. 18:375-381, 1995
 
16) 辻仲利政, 塩崎均, 村田厚夫ほか:A3食道癌に対する治療法の選択-術前化学放射線療法の有用性. 日本臨床外科医学会誌 56:1088-1094, 1995
 
17) Ohwada, S., Nakamura, S., Izumi, M. et al.:Neoadjuvant chemotherapy with etoposide, leucovorin, 5-fluorouracil and cisplatin for advanced esophageal squamous cell carcinoma. Jpn. J. Clin. Oncol. 25:79-85, 1995
PubMed
18) Ferguson, M. K., Reeder, L. B., Hoffman, P. C. et al.:Intensive multimodality therapy for carcinoma of the esophagus and gastroesophageal junction. Ann. Surg. Oncol. 2:101-106, 1995
PubMed
19) Stahl, M., Wilke, H., Fink, U. et al.:Combined preoperative chemotherapy and radiotherapy in patients with locally advanced esophageal cancer:Interim analysis of phase II trial. J. Clin. Oncol. 14:829-837, 1996
PubMed
20) 米村豊, 宮崎逸夫:術前化学療法-胃癌に対する Neoadjuvant Chemotherapy の現状と将来. 癌と化学療法 22:1893-1904, 1995
 
21) Cascinu, Catalano:Intensive weekly chemotherapy for elderly gastric cancer patients, using 5-fluorouracil, cisplatin, epi-doxorubicin, 6S-leucovorin and glutathione with the support of G-CSF. Tumori 81:1995
PubMed
22) Chari, R. S., Tyler, D. S., Anscher, M. S. et al.:Preoperative radiation and chemotherapy in the treatment of adenocarcinoma of the rectum. Ann. Surg. 221:778-787, 1995
PubMed
23) 柳泉, 古賀昭次, 麻生公ほか:肝細胞癌に対する5-FU, CDDP持続動注療法の検討. 癌と化学療法 21:2207-2210, 1994
Medical*Online
24) Olthoff, K. M., Rosove, M, H., Shackleton, C. R. et al.:Adjuvant chemotherapy improves survival after liver transplantation for hepatocellular carcinoma. Ann. Surg. 221:734-743, 1995
PubMed
25) Remick, S. C., Chmura, M., Bromberg, C. et al.:Concurrent 72-hour continuous infusion of etoposide and cisplatin in metastatic breast cancer. Ann. J. Clin. Oncol. 19:125-131, 1996
 
26) Loehrer, P. J. S., Einhorn, L. H. and Williams, S. D.:VP-16 plus ifosfamide plus cisplatin as salvage therapy in refractory germ cell cancer. J. Clin. Oncol. 4:528-536, 1986
 
27) Beroun, E. R., Nichols, C. R., Kneebone, P. et al.:Long-term outcome of patients with relapsed and refractory germ cell tumors treated with high-dose chemotherapy and autologous bone marrow rescue. Ann. lntern. Med. 117:124-128, 1992
 
28) Motzer, R. Z., Gulati, S.C., Crown, J. P. et al.:High-dose chemotherapy and autologous bone marrow rescue for patients with refractory germ cell tumors. Cancer 69:550-556, 1992
 
29) Bonomi, P. D., Finkelstein, D. M., Ruckdeschel, J. C. et al.:Combination chemotherapy versus single agents followed by combination chemotherapy in stage, non-small cell lung cancer:a study of the Eastern Cooperative Oncology Group. J. Clin. Oncol. 7:1602-1613, 1989
 
30) Klastersky, J., Sculier, J. P., Lacroix, H. et al.:A randomized study comparing cisplatin or carboplatin with etoposide in patients with advanced non-small cell lung cancer:European Organization for Research and Treatment of Cancer protocol 07861. J. Clin. Oncol. 8:1556-1562, 1990
PubMed
31) 宮永直人, 林独志, 赤座英之ほか:生存から見た癌化学療法の進歩-精巣腫瘍. 癌と化学療法 22:739-745, 1995
 
32) 犬山征夫, 福田諭, 藤井正人:生存から見た癌化学療法の進歩-頭頸部癌. 癌と化学療法 22:732-738, 1995
 
33) 波多江正紀, . 大西義孝, 前田康貴ほか:生存から見た癌化学療法の進歩-卵巣癌. 癌と化学療法 22:718-725, 1995
 
34) Consensus Development Conference Statement, Ovarian Cancer:screening, treatment and follow up. National lnt. J. Health, 1944, pp. 5-7
 
35) Rapp, E, Pater, J. L, Willan, A. et al.:Chemotherapy can prolong survival in patients with advanced non-small cell lung cancer:report of a Canadian multi-center randomized trial. J. Clin. Oncol. 6:663-641, 1988
 
36) Myrray, N., Stah, A., Osoba, D. et al.:Intensive weekly chemotherapy for the treatment of extensive-stage small-cell Iung cancer-. J. Clin. Oncol. 9:1632-1638, 1991
 
37) Huruse, K., Kubota, K., Nishiwaki, Y. et al.:Phase study of dose intensive weekly chemotherapy with recombinant human granulocyte-colony stimulating factor (G-CSF) versus standard chemotherapy in extensive stage small cell lung cancer (SCLC). Proc. Am. Soc. Clin Oncol. 15:375, 1996 (abstract)
 
38) 掘越昇, 加藤千明:抗癌剤と他剤の相互作用, およびそれらの副作用. 癌化学療法の副作用対策 (改訂版), 吉出清一編, 先端医学社, 東京, 1996, pp, 145-151
 
P.212 掲載の参考文献
1) Capizzi, R. L.:Asparaginase-methotrexate in combination chemotherapy:schedule-dependent differential effects on normal versus neoplastic cells. Cancer Treat. Rep. 65(suppl. 4):115-120, 1981
 
2) Schwartz, S. A., Morgenstern, B. and Capizzi, R. L.:Schedule-dependent synergy and antagonism between high-dose 1-β-Dar-abinofuranosylcytosine and asparaginase in the L1518Y murine leukemia. Cancer Res. 42:2191-2197, 1982
 
3) Capizzi, R. L, Poole, M., Cooper, M. R. et al.:Treatment of poor risk acute leukemia with sequential high-dose ara-C and asparaginase. Blood 63:694-700, 1984
PubMed
4) Yarbro, J. W.:Mechanism of action of hydroxyurea. Semin. Oncol. 19(suppl. 9):1-10, 1992
 
5) Tanaka, M., Kimura, K and Yoshida, S.:Mechanism of synergistic cell killing by hydroxyurea and cytosine arabinoside. Jpn. J. Cancer Res. 76:729-735, 1985
PubMed
6) Walsh, C. T., Craig, R. W. and Agarwal, R. P.:Increased activation of 1-β-D-arabinofuranosylcytosine by hydroxyurea. Cancer Res. 40:3286-3292, 1980
 
7) Schilsky, R. L, Ratain, M. J., Vokes, E. E. et al.:Laboratory and clinical studies of biochemical modulation by hydroxyurea. Semin. Oncol. 19 (suppl.9):84-89, 1992
 
8) Schilsky, R. L, Williams, S. F., Ultmann, J. E. et al.:Sequential hydroxyurea-cytarabine chemotherapy for refractory non-Hodgkin's lymphoma. J. Clin. Oncol. 5:419-425, 1987
PubMed
9) Cheson, B. D.:New metabolites in the treatment of human malignancies. Semin. Oncol. 19:695-706, 1992
 
10) Walsh, C, Speyer, J. L, Wernz, J. C. et al.:Trial based on biochemical modulation of 5 fluorouracil by daily sequential hydroxyurea in colorectal cancer. Proc. AACR 26:168, 1985
 
11) サンド医療用品医薬品相互作用一覧, 1995
 
12) Yeager, A. M., Vogelsang, G. B., Jones, R. J. et al.:Induction of cutaneous graft-versus-host disease by administration of cyclosporine to patients undergoing autologous bone marrow transplantation for acute myeloid leukemia. Blood 79:3031-3035, 1992
PubMed
13) Slater, L. M, Sweet, P., Stupecky, M. et al.:Cyclosporin A reverses vincristine and daunorubicin resistance in acute lymphatic leukemia in vitro. J. Clin. Invest. 77:1405-1408, 1986
PubMed
14) Lum, B. L, Kaubish, S., Yahanda, A. M. et al.:Alteration of etoposide pharmacokinetics and pharmacodynamics by cyclosporine in phase I trial to modulate multidrug resistance J. Clin. Oncol. 10:1635-1642, 1992
 
15) List, A. F., Spier, C., Greer, J. et al.:Phase I/II trial of cyclosporine as a chemotherapy-resistance modifier in acute leukemia. J. Clin. Oncol. 11:1652-1660, 1993
PubMed
P.223 掲載の参考文献
1) Arinaga, S., Karimine, N., Takamuku, K. et al.:A trial of adjuvant chemoimmunotherapy with mitomycin C and OK-432 for stage III gastric carcinoma. J. Surg . Oncol. 50:187-189, 1992
PubMed
2) Maehara, Y., Okuyama, T., Kakeji, Y. et al.:Postoperative immunochemotherapy including streptococcal lysate OK-432 is effective for patients with gastric cancer and serosal invasion. Am. J. Surg. 168:36-40, 1994
PubMed
3) Tanaka, N., Gouchi, A., Ohara, T. et al.:Intratumoral injection of a streptococcal preparation, OK-432, before surgery for gastric cancer. Cancer 74:3097-3103, 1994
PubMed
4) 新本稔, 服部孝雄, 玉田隆一郎ほか:胃癌治癒切除症例に対するマイトマイシンC, フトラフール, クレスチンを用いた術後免疫化学療法. Oncologia 14:171-180, 1985
 
5) 三富利夫, 生越喬二ほか:胃癌術後補助免疫化学療法剤としてのPSKの臨床効果に関する検討. 癌と化学療法 13:2532-2537, 1986
Medical*Online
6) 近藤達平, 井口潔, 服部孝雄ほか:胃癌に対するマイトマイシンC, フトラフール併用術後化学療法の効果に関する研究, 第5報, 5年生存率について. 癌と化学療法 9:2016-2024, 1982
Medical*Online
7) Nakazato, H., Koike, A., Saji, S. et al.:Efficacy of immuno-chemotherapy as adjuvant treatment after curative resection of gastric cancer. Lancet 343:1122-1126, 1994
 
8) 三富利夫, 土屋周二, 飯島登ほか:結腸.直腸癌の治癒切除症例に対するPSKによる補助免疫化学療法のrandomized controlled study. 癌と化学療法16:2241-2449, 1989
 
9) 山口晃弘, 中里博昭, 小池昭彦ほか:結腸癌に対する術後交替免疫化学療法の比較対照試験成績 (第2報). 日癌治29:1454, 1994
 
10) 種村廣巳, 佐治重豊, 宮喜一ほか:進行再発胃癌に対するレンチナンを用いた免疫化学療法の有効性に関する共同研究 (最終報告). Biotherapy 10:60-65, 1996
Medical*Online
11) 佐治重豊, 国技克行, 杉山保幸:抗腫瘍免疫機構における非特異的免疫賦活剤の役割と新しい作用機序. Oncology Frontier-癌薬物療法をめぐる最近の話題-第1部, 太田和雄, 塚越茂, 西條長宏ほか編, 先端医学社, 東京, 1996, pp.56-61
 
12) 佐治重豊ほか:担癌に伴う免疫機能低下とその対策. 癌治療と宿主 6:59-66, 1994
 
13) 鯉江久昭, 折田薫三, 細川真澄男ほか:癌免疫外科研究会宿主要因検討委員会報告. Biotherapy 5:1561-1574, 1991
 
14) 山口佳之, 宮原栄治, 桧原淳ほか:OK-432免疫療法のresponderの探索と作用機序の解明. Biothermpy 10:42-49, 1996
 
15) 枝克行, 佐治重豊, 種村廣巳ほか:胃癌術前血清IAP値からみた術後BRM療法の適応に関する検討. 日癌治 27:1713-1721, 1992
 
16) Ogoshi, K., Kondoh, Y., Tajima, T. et al.:Glycosidically bound sialic acid levels as a predictive marker of postoperative adjuvant therapy in gastric cancer. Cancer Immunol. Immunother. 35:175-180, 1992
PubMed
17) 吉野肇一, 春山克郎, 中村修三ほか:生存率からみた脾摘の意義-胃癌手術における脾摘の意義, 問題点, 日消外会誌 12:944-949, 1979
 
18) 杉町圭蔵, 児玉好史, 岡村健ほか:胃全摘における脾摘-予防的脾摘批判の立場から. 手術 36:337-343, 1982
 
19) 山岸久一, 内藤和世, 前田米造ほか:OK-432免疫療法における脾臓の役割と誘導されるeffector細胞の性格解析. 癌と化学療法 10:1670-1678, 1983
Medical*Online
20) 佐治重豊, 国枝克行:胃癌をめぐる脾摘の問題点, 特に術後免疫化学療法と脾摘の功罪. 消化器癌 1:165-172, 1991
 
21) 橋本嘉幸, 北条博史:免疫賦活剤の肝薬物代謝酵素に対する影響. 癌と化学療法 (臨時増刊II) 6:257-262, 1979
 
22) 羽室淳爾:生体防御とがん. レンチナンと新しい臨床展望. 講談社, 東京, 1994
 
23) 羽室淳爾, 嶌村俊朗, 鈴木学:Lentinanの新しい適用法についての基礎からの提言. Biotherapy 10:72-82, 1996
Medical*Online
24) 佐治重豊, 木田恒, 国枝克行ほか:胃癌術後長期免疫化学療法施行例の遠隔成績について. Prog. Med. 5:485-492, 1985
 
25) 中里博昭, 小池明彦, 佐治重豊ほか:胃癌切除症例に対するPSKの評価. Biotherapy 4:884-891, 1990
 
26) 細川真澄男:Chemoimmunomodulationの応用. Mebio (9):6-10, 1993
 
27) Glaser, M.:Regulation of specific cell-mediated cytotoxic response against SV 40-induced tumor associated antigens by depletion of suppressor T-cells with cyclophosphamide. J. Exp. Med. 149:774-779, 1979
PubMed
28) 細川真澄男, 袁嵐:BRMと化学療法-基礎の立場から. Biotherapy 10:574-580, 1996
Medical*Online
29) North, R. J.:Cyclophosphamide-facilitated adoptive immunotherapy of established tumor depends on elimination of tumor induced suppressor T cells. J. Exp. Med. 155:1063-1074, 1982
PubMed
30) 河合雅彦:OK-432とrecombinant interleukin-2脾内投与により誘導される活性化脾細胞の活性増強法に関する実験的研究. 岐阜大医紀 40:752-767, 1992
 
31) 日下部光彦:担癌生体における好中球機能と抗腫瘍活性に関する研究 (II). OK-432およびrhG-CSFを用いたラット好中球の貧食活性と抗腫瘍作用の増強法に関する実験的研究. 岐阜大医紀 43:136-145, 1995
 
32) Van der Bruggen, P., Traversari, C., Chomez, P. et al.:A gene encoding an antigen recognized by cytotoxic T lymphocytes on a human melanoma . Science 254:1643-1647, 1991
PubMed
P.238 掲載の参考文献
1) 小長谷昌功, 斎藤早久良:IFNの生物活性, 作用機序, 情報伝達. インターフェロン療法, 高久史麿, 北村聖編, メディカルレビュー社, 大阪, 1993, pp.37-47
 
2) Williams, S.J., Baird-Lanmbert, J. A. and Farrell, G. C.:Inhibition of theophylline metabolism by interferon. Lancet ii:939-941, 1987
 
3) Sakai, H., Okamoto, T. and Kikkawa, Y.:Suppression of hepatic drug metabolism by the interferon inducer, polyriboinosinic acid polyribocitidylic acid. J. Pharmacol. Exp. Ther. 263:381-386, 1992
PubMed
4) 北田光一:IFNの生物活性, 作用機序, 情報伝達. 月刊薬事 38:467-497, 1996
 
5) Okuno, H., Takasu, M., Kano, H. et al.:Depression of drug-metabolizing activity in the human liver by interferon-β. Hepatology. 17:65-69, 1993
 
6) 北村諭:間質性肺疾患,の概念, 病因および分類. 日内会誌 83:705-711, 1994
 
7) 村田朗, 工藤翔二:薬物性肺臓炎. 日内会誌 83:768-733, 1994
 
8) 中川敏幸ほか:HAMにおける肺病変:α‐インターフェロン投与後に肺病変の増悪を来した1例. 呼吸 8:331-335, 1989
 
9) Wadler, S. and Wiernik, P. H.:Clinical up date on the role of fluorouracil and recombinant interferon alfa-2a in the treatment of colorectal carcinoma. Semin. Oncol. 17:16-21, 1990
 
10) 竹山英夫ほか:小柴胡湯およびインターフェロンの投与が奏効した成人T細胞白血病の1例. Biotherapy 5:1719-1722, 1991
 
11) 厚生省薬務局:インターフェロンα製剤および小柴胡湯と間質性肺炎. 医薬品副作用情報, No.118:2, 1993
 
12) 厚生省特定疾患難治性の肝炎調査研究班平成5年度研究報告書, 1993, pp.7-11
 
13) 野口友之ほか:インターフェロン投与後の間質性肺炎の1例. 治療学と 27:1241-1244, 1993
 
14) 星野恵津夫ほか:本邦におけるインターフェロンによる間質性肺炎の特徴. 日消誌92 (臨時増刊号, 第37回大会):1553, 1995
 
15) Andreone, P., Cursaro, C. and Gasbarrini, G.:Interferon-α increases prostaglandin E2 production by cultured liver biopsy in patients with chronic viral hepatitis. J. Hepatol. 19:228-231, 1993
 
16) Andreone, P., Cursaro, C., Gramenzi. A. et al.:Indomethacin increases 2'-5'-oligoadenylate synthetase release by cultured liver tissue of patients with HCV chronic active hepatitis. Int. Hepatol. Commun. 2:289-294, 1994
 
17) Hendrix, C. W., Petty, B.G., Woods, A. et al.:Modulation of α-interferon's antiviral and clinical effects by aspirin, acetaminophen, and prednisone in healty volunteers. Antiviral Res. 28:121-131, 1995
 
18) Hill, N.O., Pardue, A., Khan, A. et al.:Interferon and cimetidine for malignant melanoma. Lancet i:286, 1983
 
P.247 掲載の参考文献
1) Swain, S. M.:Endocrine therapies of cancer. In:Cancer Chemotherapy and Biotherapy, Principles and Practice, 2nd ed., ed. by Chabner, B.A. and Longo, D.L, Lippincott-Raven, Philadelphia, 1996 pp. 59-108
 
2) Wolf, D. M., Langan, F. S., Parker, C. J. et al.:Investigation of the mechanism of tamoxifen stimulated breast tumor growth with nonisomerizable analogues of tamoxifen and metabolites. J. Natl. Cancer lnst. 85:806-812, 1993
 
3) Lien, E. A., Anker, G., Lonning, P. E. et al.:Decreased serum concentrations of tamoxifen and its metabolites induced by aminoglutethimide. Cancer Res. 50:5851-5857, 1990
PubMed
4) Furr, B. J. and Jordan, V. C.:The pharmacology and clinical uses of tamoxifen (review). Pharmacol. Ther. 25:127-205, 1984
PubMed
5) Fabian, C., Sternson, L., El, S. M. et al.:Clinical pharmacology of tamoxifen in patients with breast cancer:correlation with clinical data. Cancer 48:876-882, 1981
 
6) Fabian, C., Sternson, L. and Barnett, M.:Clinical pharmacology of tamoxifen in patients with breast cancer:comparison of traditional and loading dose schedules. Cancer Treat. Rep. 64:765-773, 1980
PubMed
7) Lyman, S. D. and Jordan, V. C.:Metabolism of nonsteroidal antiestrogens. In:Estrogen/Antiestrogen Action and Breast Cancer Therapy, ed. by Jordan, V. C., University of Wisconsin Press, Madison, 1986, p. 191
 
8) Daniel, C.P., Gaskell, S.J., Bishop, H. et al.:Determination of tamoxifen and an hydroxylated metabolite in plasma from patients with advanced breast cancer using gas chromatograhymass spectrometry. J. Endocrinol. 83:401-408, 1979
 
9) Langan, F.S., Tormey, D. C. and Jordam, V. C.:Tamoxifen metabolites in patients on long-term adjuvant therapy for breast cancer. Eur. J. Cancer 26:883-888, 1990
 
10) Santen, R. J., Manni, A. Harvey, H. et al.:Endocrine treatment of breast cancer in women (Review). Endo. Rev. 11:221-65, 1990
 
11) Murad, F. and Kuret, J.A.:Estrogens and progestins. In:The Pharmacological Basis of Therapeutics, ed. by Goodman, G.A., Rall, T.W., Nies, A.S. et al., MacGraw-Hill, New York, 1990, p. 1384
 
12) Fotherby, K. and James, F.:Metabolism of synthetic steroids. Adv. Steroid Biochem. Pharmacol. 3:67, 1972
 
13) Tamassia, V., Battaglia, A., Ganzina, F. et al.:Pharmacokinetic approach to the selection of does schedules for medroxyprogesterone acetate in clincal oncology. Cancer Chemother. Pharmacol. 8:151-156, 1982
 
14) Henderson, I.C.:Endocrine therapy in metastatic breast cancer. In:Breast Diseases, ed. by Harris, J. R., Hellman, S., Henderson, I.C. et al., JB Lippincott, Philadelphia, 1991, p. 559
 
15) Gallagher, C.J., Cainduff, F. and Smith, I.E.:High does versus low dose medroxyprogesterone acetate:a randomized trial in advanced breast cancer. Eur. J. Cancer Clin. Oncol. 23:1895-1900, 1987
 
16) Cavalli, F., Goldhirsch, A., Jungi, F. et al.:Randomized trial of low-versus high-dose medroxyprogesterone acetate in the induction treatment of postmenopausal patients with abvanced breast cancer. J. Clin. Oncol. 2:414-419, 1984
PubMed
17) Pannuti, F., Martoni, A., Di, M.a. et al.:Prospective, randomized clinical trial of two different high dosages of medroxyprogesterone acetate (MAP) in the treatment of rnetastatic breast cancer. Eur. J. Cancer 15:593-601, 1979
 
18) Bishop, J.F, Smith, J.G, Jeal, P. N. et al.:The effect of danazol on tumour control and weight loss in patients on tamoxifen therapy for advanced breast cancer:a randomized double-blind placebo controlled trial. Eur. J. Cancer 29A:814-818, 1993
PubMed
19) Ingle, J.N., Twito, D.I., Schaid, D.J. et al.:Combination hormonal therapy with tamoxifen plus fluoxymesterone versus tamoxifen alone in postmenopausal women with metastatic breast cancer. An update analysis. Cancer 67:886-891, 1991
PubMed
20) Tormey, D.C, Lippman, M.E., Edwards, B.K. et al.:Evaluation of tamoxifen doses with and without fluoxymesterone in advanced breast cancer. Ann. Intern. Med. 98:139-144, 1983
PubMed
21) Powles, T.J., Ashley, S., Ford, H.T. et al.:Treatment of disseminated breast cancer with tamoxifen, aminoglutethimide, hydrocortisone, and danazol, used in combination or sequentially. Lancet i:1369-1373, 1984
PubMed
22) Mouridsen, H.T., Salimtschik, M., Dombernowsky, P. et al.:Therapeutic effect of tamoxifen versus combined tamoxifen and diethylstilbestrol in advanced breast cancer in postmenopausal women. Eur. J. Cancer 1:107-110, 1980
 
23) Rose, C., Kamby, C., Mouridsen, H.T. et al.:Combined endocrine treatment of postmenopausal patients with advanced breast cancer. A randomized trial of tamoxifen vs. tamoxifen plus aminoglutethimide and hydrocortisone. Br. Cancer Res. Treat. 7 (suppl.):S45-S50, 1986
 
24) Smith, I.E., Harris, A.L., Morgan, M. et al.:Tamoxifen versus aminoglutethimide versus combined tamoxifen and aminoglutethimide in the treatment of advanced breast carcinoma. Cancer Res. 42 (8 suppl.):S3405-S3408, 1982
 
25) Corkery, J., Leonard, R.C., Henderson, I.C. et al.:Tamoxifen and aminoglutethimide in advance breast cancer. Cancer Res. 42 (8 suppl.):S3409-S3414, 1982
 
26) Ingle, J. N., Green, S.J., Ahman, D.L. et al.:Randomized trial of tamoxifen alone or combined with aminoglutethimide and hydrocortisone in women with metastatic breast cancer. J. Clin. Oncol. 4:958-964, 1986
PubMed
27) Reid, A.D., Horobin, J. M., Newman, E.L. et al.:Tamoxifen metabolism is altered by simultaneous administration of medroxyprogesterone acetate in breast cancer patients. Br. Cancer Res. Treat. 22:153-156, 1992
 

Part3: 各臓器癌に対する多剤併用療法の薬物間相互作用

P.261 掲載の参考文献
1) Schantz, S.P., Harvison, L.B., Hong, W.K. et al.:Cancer of the head and neck. In:Cancer, Principles and Practice of Oncology, 4th ed., J.B. Lippincott, Philadelphia, 1993, pp.574-672
 
2) Chabner, B.A.:Anticancer drugs. In:Cancer, Principles and Practice Of Oncology, 4th ed., J. B. Lippincott, Philadelphia, 1993, pp.325-417
 
3) Levitt, M., Mosher, M.B., Deconti, R.C. et al.:Improved therapeutic index of methotrexate with "Leucovorin rescue". Cancer Res. 33:1729-1734, 1973
PubMed
4) Woods, R.L, Fox, R.X., Tattersall, M.H. et al.:Methotrexate treatment of advanced head and neck cancer. Cancer 48:1061-1072, 1981
 
5) DeConti, R.C. and Schoenfeld, D.:A randomized prospective comparison of intermittent methotrexate, methotrexate with leucovorin, and a methotrexate combination in head and neck cancer. Cancer 48:1061-1011, 1981
 
6) Taylor, S.G., McGire, W.P., Hauck, W.W. et al.:A randomized comparison of high-dose infusion methotrexate versus standard-dose weekly therapy in head and neck cancer. J. Clin. Oncol. 2:1006-1072, 1984
 
7) Inuyama, Y., Miyake, H., Horiuchi, M. et al.:An early phase II clinical study of cis-diammine glycolate platinum, 254-S, for head and neck cancers. Jpn. J. Cancer Chemother. 19:863-869, 1992
 
8) Inuyama, Y., Miyake, H., Horiuchi, M. et al.:An late phase II clinical study of cis-diammine glycolate platinum, 254-S, for head and neck cancers. Jpn. J. Cancer Chemother. 19:871-877, 1992
 
9) Calvert, A. H., Newell, D.R., Gumbrell, L.A. et al.:Carboplatin dosage:prospective evaluation of a simple formula based on renal function. J. Clin. Oncol. 11:1748-1756, 1989
PubMed
10) Sorensen, Rt, Stromgren, A., Jakobson, P. et al.:Is creatinine clearance a sufficient measurement for GFR in carboplatin dose calculation? Eur.J. Cancer 29 (suppl.6):S110, 1993
 
11) Scanlon, K.J., Newman, E.M., Priest, D.G. et al.:Biochemical basis for cisplatin and 5-fluorouracil synergism in human ovarian carcinoma cells. Proc. Natl. Acad. Sci. USA 83:8923-8925, 1986
PubMed
12) Esaki, T., Nakano, S., Tatsumoto, T. et al.:Inhibition by 5-fluorouracil of cis-diamminedichloroplatinum (II) induced DNA interstrand cross-link removal in an HST-1 human squamous carcinoma cell line. Cancer Res. 52:6501-6506, 1992
 
13) Kuroki, M., Nakano, S., Mitsugi, K. et al.:In vivo comparative therapeutic study of optimal administration of 5-fluorouracil and cisplatin using a newly established HST-1 human squamous carcinoma cell line. Cancer Chemother. Pharmacol. 29:273-276, 1992
PubMed
14) Vokes, EE, Choi, K. E., Schilsky, R.L. et al.:Cisplatin, fluorouracil, and high-dose leucovorin for recurrent or metastatic head and neck cancer. J. Clin. Oncol. 6:618-626, 1988
PubMed
15) Vokes, E. E., Schilsky, R.L, Weichselbaum, R.R. et al.:Induction chemotherapy with cisplatin, fluorouracil, and high-dose leucovorin for locally advanced head and neck cancer:a clinical and pharmacologic analysis. J.Clin.Oncol. 8:618-626, 1990
 
16) Dreyfness, A.I., Clark, JR, Wright, J.E. et al.:Continuous-infusion high dose leucovorin with 5-fluorouracil and cisplatin for untreated stage IV carcinoma of the head and neck. Ann. Intern. Med. 112:167-172, 1990
 
17) Sotos, G.A., Grogan, L., Allegra, C.J. et al.:Preclinical and clinical aspects of biomodulation of 5-fluorouracil. Cancer Treatment Review 20:11-49, 1994
PubMed
18) Chu, E., Zinn, S., Boarman, D. et al.:Interferon of γ interferon and 5-fluorouracil in the H630 human colon carcinoma cell line. Cancer Res. 50:5834-5840, 1990
 
19) Wadler, S. and Wiernik, P.H.:Clinical update on the role of fluorouracil and recombinant interferon alfa-2a in the treatment of colorectal cancer. Semin. Oncol. 17:16-21, 1990
PubMed
20) Vokes, E.E., Ratain, M.J., Mick, R. et al.:Cisplatin, fluorouracil, and leucovorin augmented by interferon alfa-2b in head and neck cancer:a clinical and pharmacologic analysis. J.Clin. Oncol. 11:360-368, 1993
PubMed
21) Fujii, M., Kanzaki, J., Satake, B. et al.:Early phase II study of S-1 in patients with advanced head and neck cancer. Proc. ASCO 15:894, 1996
 
22) Lokiec, F.:Drug interaction in cancer chemotherapy. In:Princple of Antineoplastic Drug Development and Pharmacology, New York, 1996 pp.189-202
 
23) 木邑道夫:ソリブジンとフルオロウラシル系薬剤との併用による薬剤の教訓. 薬理と治療 22:1635-1639, 1994
 
24) Planting, A.S.T., Vermorken, J.B., Catimel, G. et al.:Randomized phase II study of weekly cisplatin with or without amifostin in patients with head and neck cancer. Proc. ASCO 15:887, 1996
 
P.274 掲載の参考文献
1) Roth, J. A. and Putnam, J. B. Jr.:Surgery for cancer of the esophagus. Semin. Oncol. 21:453-461, 1994
PubMed
2) Ablgren, J. D.:Esophageal cancer:chemotherapy and combined modalities. Gastrointest. Oncol. 11:135-147, 1992
 
3) Ajani, J. A.:Contributions of chemotherapy in the treatment of carcinoma of esophagus:results and commentary. Semin. Oncol. 21:474-482, 1994
PubMed
4) Al-Serraf, M., Drelichman, A., Peppard, S. et al.:Adjuvant cisplatium and 5-fluorouracil 96 hour infusion in previously untreated epidermoid cancer of the head and neck (abstract). Proc. Am Assoc. Cancer Res. Am. Soc. Clin. Oncol. 22:428, 1981
 
5) Scanlon, K. J., Newman, E. M., Lu, Y. et al.:Biochemical basis for cisplatin and 5-fluorouracil synergism in human ovarian carcinoma cells. Proc. Natl. Acad. Sci. USA 83:8923-8925, 1986
PubMed
6) Shirasaka, T., Shimamoto, Y., Ohshimo, H. et al.:Metabolic basis of the synergistic antitumor activities of 5-fluorouracil and cisplatin in rodent tumor models in vivo. Cancer Chemother. Pharmacol. 32:167-172, 1993
PubMed
7) Kelsen, D. P., Cvitkovic, E., Bains, M. et al.:Cis-dichlorodiammineplatium(II) and bleomycin in the treatment of esophageal carcinoma. Cancer Treat. Res. 62:1041-1046, 1978
 
8) Ilson, D. H. and Kelsen, D. P.:Combined modality therapy in the treatment of esophageal cancer. Semin. Oncol. 21:493-507, 1994
PubMed
9) Harskovic, A., Martz, K., Al-Sarraf, M. et al.:Combined chemotherapy and radiotherapy alone in patients with cancer of the esophagus. N. Engl. J. Med. 326:1593-1598, 1992
PubMed
10) Walsh, T. N., Noonan, N., Hollywood, D. et al.:A comparison of multimodal therapy and surgery for esophageal adenocarcinoma. N. Engl. J. Med. 335:462-467, 1996
PubMed
11) Franklin, R., Steiger, Z., Vashampayan, G. et al.:Combined modality therapy for esophageal squamous cell carcinoma. Cancer 51:1062-1071, 1983
 
12) Leichman, L., Steiger, Z., Seydel, H. G. et al.:Preoperative chemotherapy and radiation therapy for patients with cancer of the esophagus:a potentially curative approach. J. Clin. Oncol. 2:75-79, 1984
PubMed
13) Poplin, E., Fleming, T., Leichman, L. et al.:Combined therapies for squamous-cell carcinoma of the esophagus, a Southwest Oncology Group Study (SWOG-8037). J. Clin. Oncol. 5:622-628, 1987
 
14) Seydel, H. G., Leichman, L., Byhardt, R. et al.:Preoperative radiation and chemotherapy for localized squamous cell carcinoma of the esophagus:a RTOG Study. lnt. J. Radiat. Oncol. Biol. Phys. 14:33-35, 1988
 
15) Forastiere, A. A., Perez-Tamayo, C. and Orringer, M. B.:Reply. J. Clin. Oncol. 8:1286-1287, 1990
 
16) Forastiere, A. A., Orringer, M. B., Perez-Tamayo, C. et al.:Preoperative chemoradiation followed by transhiatal esophagectomy for esophagus:final report. J. Clin. Oncol. 11:1118-1123, 1993
PubMed
17) Leichman, L., Herskovic, A., Leichman, C. G. et al.:Nonoperative therapy for squamous-cell cancer of the esophagus. J. Clin. Oncol. 5:365-370, 1987
PubMed
18) Coia, L. R., Engstrom, P. F. and Paul, A.:Nonsurgical management of esophageal cancer:report of a Study of Combined Radiotherapy and Chemotherapy. J. Clin. Oncol. 5:1783-1790, 1987
PubMed
19) Coia, L. R., Engstrom, P. F., Paul, A. R. et al.:Long-term results of infusional 5-FU, mitomycin-C, and radiation as primary management of esophageal carinoma. lnt. J. Radiat. Oncol. Biol. Phys. 20:29-36, 1991
 
20) Al-Sarraf, M., Martz, K., Herskovic, A. et al.:Progress peport of combined chemoradiotherapy versus radiotherapy alone in patients with esophageal cancer:an intergroup study. J. Clin. Oncol. 15:277-284, 1997
 
21) Ajani, J. A., Ilson, D. H., Duagherty, K. et al.:Paclitaxel in the treatment of carcinoma of the esophagus. Semin. Oncol. 22 (suppl. 6):35-40, 1995
 
22) Taguchi, T., Wakui, A., Nabeya, K. et al.:254-S Gastrointestinal Cancer Study Group:a phase 2 clinical study of cis-diammine glycolato platium, 254-S, for gastrointestinal cancer. Jpn. J. Cancer Chemother. 19:483-488, 1992
 
P.286 掲載の参考文献
1) Preusser, P., Wilke, H., Achterrath, W. et al.:Advanced gastric carcinoma:a phase II study with etoposide(E), adriamycin(A) and split course cisplatin(P)=EAP. Proc. Am. Soc. Clin. Oncol. 6:75, 1987 (abstr.)
 
2) 島田安博, 吉田茂昭, 大津敦ほか:進行胃癌に対するEAP療法の第II相試験. 日癌治 25:2102, 1990
 
3) Kelsen, D., Atiq, O.T., Saltz, L. et al.:FAMTX versus etoposide, doxorubicin, and cisplatin:a random assignment trial in gastric cancer. J. Clin. Oncol. 10:541-548, 1992
PubMed
4) Kish, J., Drelichman, A., Jacobs, J. et al.:Clinical trials of cis-plantin and 5-fluorouracil infusion as initial treatment of advanced squamous cell carcinoma of the head and neck. Cancer Treat. Rep. 66:471-474, 1982
 
5) Ohtsu, A., Shimada, Y., Yoshida, S. et al.:Phase II study of protracted infusional 5-fluorouracil combined with cis-platinum for advanced gastric cancer:report from the Japan Clinical Oncology Group (JCOG). Eur. J. Cancer 30A:2091-2093, 1994
PubMed
6) Kurihara, M., Izumi, T., Yoshida, S. et al.:A cooperative randomized study on tegafur plus mitomycin C versus combined tegafur and uracil plus mitomycin C in the treatment of advanced gastric cancer. Jpn. J. Cancer Res. 82:613-620, 1991
 
7) 島田安博, 大津敦, 兵頭一之介ほか:切除不能進行胃がんに対する無作為化比較試験JCOG9205-中間解析結果. 日癌治 31:608, 1996
 
8) 村上稔, 太田和雄, 宮崎保ほか:多施設共同研究によるメソトレキセート・5-FU交代療法の進行胃癌および結腸.直腸癌に対するPhase II Study. 癌と化学療法 14:2482-2490, 1987
Medical*Online
9) 佐々木常雄, 太田和雄, . 井林淳ほか:胃癌に対するメソトレキセート・5-FU交代療法と5-FU単独療法の比較試験. 癌と化学療法 16:2545-2555, 1989
Medical*Online
10) 山道昇, 白尾國昭, 兵頭一之介ほか:切除不能進行胃がんに対する MTX+5-FU時間差療法の第II相試験-JCOG Trial-. 日癌治 30:1317, 1995
 
11) Klein, H. O., Dias Wickramanayake, P., Dieterle, F. et al.:Chemotherapieprotokoll zur Behandlung des metastasierenden Magenkarzinoms. Dtsch. Med. Wochenschr. 107:1708-1712, 1982
 
12) Wils, J., Klein, H., Wagener, D. J. Th. et al.:Sequential high-dose methotrexate and fluorouracil combined with doxorubicin a step ahead in the treatment of advanced gastric cancer:a trial of the European Organization for Research and Treatment of Cancer Gastrointestinal Tract Cooperative Group. J. Clin. Oncol. 9:827-831, 1991
 
13) 白尾国昭, 島田安博, 斉藤大三ほか:手術不能進行胃がんに対する CPT-11+CDDP併用療法-Phase I-II Study-. 日癌治 29:1117, 1994
 
14) 室圭, 大津敦, 朴成和ほか:切除不能進行胃がんに対するCDDP+CPT-11併用療法の第II相臨床試験. 日癌治31:610, 1996
 
15) Shimada, Y., Sasaki, Y., Sugano, K. et al:Combination phase I study of CPT-11(Irinotecan) combined with continuous infusion of 5-fluorouracil (5-FU) in metastatic colorectal cancer. Proc. Amer. Soc. Clin. Oncol. 12:196. 1993
 
16) Simultaneous administration of CPT-11 and fluorouracil:Alteration of the pharmacokinetics of CPT-11 and SN-38 in patients with advanced colorectal cancer. J. Natl. Cancer Inst. 86:1096, 1994
PubMed
P.300 掲載の参考文献
1) Labianca, R., Pessi, A., Facendola, G. et al.:Modulated 5-fluorouracil (5-FU) regimens in advanced colorectal cancer:a critical review of comparative studies. Eur. J. Cancer 32A (suppl. 5):S7-S12, 1996
 
2) Schmoll, H.-J.:Development of treatment for advanced colorectal cancer:infusional 5-FU and the role of new agents. Eur. J. Cancer 32A (suppl. 5):S18-S22, 1996
 
3) Cutsem, E. V.:A glimpse of the future. New directions in the treatment of colorectal cancer. Eur. J. Cancer 32A (suppl. 5):S23-S27, 1996
 
4) Immergut, M.:Carcinoma of the bladder:a death associated with the toxicity of combined therapy with 5-fluorouracil and cobalt irradiation. J.Urol. 99:169-171, 1968
PubMed
5) 的場敏明, 八木義弘, 木所昭夫ほか:Methotrexate/5-FU交代療法におけるmethotrexateの作用機序. 日癌治 30:861-866, 1995
 
6) Advanced colorectal cancer meta-analysis project:meta-analysis of randomized trials testing the biochemical modulation of fluorouracil by methotrexate in metastatic colorectal cancer. J. Clin. Oncol. 12:960-969, 1994
PubMed
7) Harvey, V.J., Slevin, M. L. and Dilloway, M. R.:The influence of cimetidine on the pharmacokinetics of 5-fluorouracil. Br.J.Clin. Pharmacol. 18:421-430, 1984
PubMed
8) Bruckner, H. W. and Creasey, W. A.:The administration of 5-fluorouracil by mouth. Cancer 33:14-18, 1974
PubMed
9) 佐々木常雄:Biochemical modulation(化学療法の効果増強). 血液.腫瘍科 34:64-71, 1997
 
10) Bardakji, Z., Jolivel, J., Langelier, Y. et al.:5-fluorouracil-metronidazole combination therapy in metastatic colorectal cancer. Cancer Chemoth. Pharmacol. 18:140-144, 1986
 
11) Wajima, T.:Possible interaction between warfarin and 5-fluorouracil. Am.J.Hematol. 40:238, 1992
PubMed
12) Rowan, T., Chlebowski, R.T., Gota, C. H. et al.:Clinical and pharmacokinetic effects of combined warfarin and 5-fluorouracil in advanced colon cancer. Cancer Res. 42:4827-4830, 1982
 
13) Howell, S. B., Wung, W. E, Taetle, R. et al.:Modulation of 5-fluorouracil toxicity by allopurinol in man. Cancer 48:128-1289, 1981
 
14) Kroener, J. F. and Saleh, F. and Howell, S. B.:5-FU and allopurinol:toxicity modulation and phase II result in colon cancer. Cancer Treat. Rep. 66:1133-1137, 1982
PubMed
15) Wadler, S., Schwartz, E, Goldman, M. et al.:Fluorouracil and recombinant alpha-2a-interferon;an active regimen against advanced colorectal cancer. J.Clin.Oncol. 7:1769-1775, 1989
PubMed
16) Kosmidis, P. A., Tsavaris, N., Skarlos, D. et al.:Fluorouracil and leucovorin with or without interferon alfa-2b in advanced colorectal cancer:analysis of a prospective randomized phase III trial. J.Clin. Oncol. 14:2682-2687, 1996
PubMed
17) Seymour, M. T., Slevin, M. L, Kerr, D.J. et al.:Randomized trial assessing the addition of interferon α-2a to fluorouracil and leucovorin in advanced colorectal cancer. J.Clin. Oncol. 14:2280-2288, 1996
 
18) Walker, D. A., Pillow, J. and Waters, K. D.:Enhanced cis-platinum ototoxicity in children with brain tumors who have received stimultaneous or prior cranial irradiation. Med.Pediatr.Oncol. 17:48-52, 1989
PubMed
19) Gonzalez-Vitale, J.C.,Hayes, D.M. and Cvitkovic, E.:Acute renal failure after cis-dichlorodiammineplatinum(II) and gentamicincephalothin therapies. Cancer Treat.Rep. 62:693-698, 1978
PubMed
20) Haas, A.:The influence of aminoglycoside on the nephrotoxicity of cis-diamminedichloroplatinum in cancer patients. J.lnfect.Dis. 147:363, 1983
PubMed
21) Grossman, S. A., Sheidler, V. R. and Gilbert, M. R.:Decreased phenytoin level in patients receiving chemotherapy. Am.J.Med. 87:505-510, 1989
PubMed
22) Neef, C.:An interaction between cytostatic and anticonvulsant drugs. Clin. Pharmacol. Ther. 43:372-375, 1988
PubMed
P.312 掲載の参考文献
1) Matsui, O., Kadoya, M., Yoshikawa, J. et al.:Small hepatocellular carcinoma:treatment with subsegmental transcatheter arterial embolization. Radiology 188:79-83, 1993
PubMed
2) 谷川久一:内科からみた肝細胞癌の治療方針. 外科診療 38:265-270, 1996
Medical*Online
3) Lai, E., Choi, T. K., Cheng, C. H. et al.:Doxorubicin for unresectable hepatocellular carcinoma. Cancer 66:1685-1687, 1990
PubMed
4) Patt, Y., Yoffe, B., Charnsangavej, C. et al.:Low serum alpha-fetoprotein level in patients with hepatocellular carcinoma as a predictor of response to 5-FU and interferon-alpha-2b. Cancer 72:2574-2582, 1993
PubMed
5) Cheng, AL., Chen, Y.C., Yeh, K.H. et al.:Chronic oral etoposide and tamoxifen in the treatment of far-advanced hepatocellular carcinoma. Cancer 77:872-877, 1996
PubMed
6) 荒井保明, 木戸長一郎, 太田和雄ほか:皮下埋め込み式リザーバーを利用した動注化学療法:臨床60例の検討と新しい薬剤投与法の可能性 (第一報:技術面について). 癌と化学療法12:270-277, 1985
 
7) Wagner, J., Gyves, J., Stetson, P. et al.:Steady-state nonlinear pharmacokinetics of 5-fluorouracil during hepatic arterial and intravenous infusions in cancer patients. Cancer Res. 46:1499-1506, 1986
PubMed
8) Nakamura, K., Takashima, S., Takada, K. et al.:Clinical evaluation of intermittent arterial infusion chemotherapy with an implanted reservoir for hepatocellular carcinoma. Cancer Chemother. Pharmacol. 31:S93-S98, 1992
PubMed
9) Yodono, H., Takekawa, S., Tarusawa, K. et al.:Combination therapy consist of arterial infusion chemotherapy(EPF,EAP) and transcatheter arterial embolization (TAE). Cancer Chemother. Pharmacol. 33:S79-S83, 1994
PubMed
10) Yoshikawa, M., Saosho, H., Ebara, M. et al.:A randomized trial of intrahepatic arterial infusion of 4'-epidoxorubicin with lipiodol versus 4'-epidoxorubicin alone in the treatment of hepatocellular carcinoma. Cancer Chemothez Pharmacol. 33:S149-S152, 1994
 
11) Iwayama, T., Sawada, S. and Ohta, Y.:Repeated arterial infusion chemotherapy for inoperable hepatocellular carcinoma using an implantable drug delivery system. Cancer Chemother. Pharmacol. 33:S134-S138, 1994
 
12) Oka, M., Hazama, S., Yoshino, S. et al.:Intraarterial combined immunochemotherapy for unresectable hepatocellular carcinoma:preliminary results. Cancer Chemother. Pharmacol. 33:S194-S200, 1994
 
13) 元原智文, 小沢善, 森田荘二郎:高度進行肝細胞癌に対するリザーバー動注の位置付け. 癌と化学療法 21:2645-2648, 1994
Medical*Online
14) 小川隆平, 中村健治, 高田恵二ほか:原発性肝癌に対する皮下埋め込み式動注ポートを用いた間歇的動注療法. 日消誌 91:171-179, 1994
Medical*Online
15) 村田貴史, 宇田光伸, 永田憲司ほか:Mitoxantroneを用いた進行原発性肝癌の反復動注療法の経験. 癌と化学療法 21:1991-1996, 1994
Medical*Online
16) Patt, Y. Z., Charnsangavej, C., Yoffe, B. et al.:Hepatic arterial infusion of floxuridine, leucovorin, doxorubicin, and cisplatin for hepatocellular carcinoma:effects of hepatitis B and C virus infection on drug toxicity and patient survival. J. Clin. Oncol. 12:1204-1211, 1994
 
17) Toyoda, H., Nakano, S., Kumada, T. et al.:The efficacy of continuous local arterial infusion of 5-fluorouracil and cisplatin through an implanted reservoir for severe advanced hepatocelular carcinoma. Oncology 52:295-299, 1995
 
18) 柳泉, 古賀昭次, 麻生公ほか:肝細胞癌に対する5FU, CDDP持続動注療法の検討. 癌と化学療法21:2207-2210, 1994
 
19) 谷川久一, 田中正俊:肝細胞癌, 胆道癌, 膵臓の化学療法. 最新癌化学療法, 漆崎一朗編メディカルレビュー社, 大阪, 1996, pp.257-269
 
20) 赤沢修吾, 大和明子:大腸癌に対するCisplatin (CDDP)/5-fluorouracil (5-FU) 併用療法. 癌と化学療法23:1770-1779, 1996
 
P.320 掲載の参考文献
1) Gralla, R.J., Casper, E.S., Kelsen,D.P. et al.:Cisplatin and vindesine combination chemotherapy for advanced carcinoma of the lung:a randomized trial investigating two dosage schedules. Ann. Intern. Med. 95:414-420, 1981
 
2) Kunitoh,H., Watanabe,K., Onoshi,T. et al.:Phase II trial of docetaxel in previously untreated advanced non-small-cell lung cancer:a Japanese Cooperative study. J.Clin. Oncol. 14:1649-1655, 1996
PubMed
3) Le Chevalier,T., Belli, L., Monnier,A. et al.:Phase II study of docetaxel (Taxotere) and cisplatin in advanced non small cell lung cancer (NSCLC):an interim analysis. Proc. Am. Soc. Clin. Oncol. 14:A1059, 1995
 
4) Zalcberg,J.R., Bishop, J.F., Millward, M. J. et al.:Preliminary results of the first phase II trial of docetaxel in combination with cisplatin on patients with metastatic or locally advanced non-small cell lung cancer (NSCLC). Proc. Am. Soc. Clin. Oncol. 14:A1062, 1995
 
5) Watanabe,K., Hayashi,I., Hiraki,S. et al.:Phase I/II dose escalation study of docetaxel (TXT) and cisplatin (CDDP) for stage IV non-small cell lung cancer (NSCLC). Proc. Am. Soc. Clin. Oncol. 16:254a, 1997
 
6) Kamataki,T., Yokoi,T., Yamayoshi, Y. et al.:Strategic proposals to avoid toxic drug interactions during new drug development:molecular toxicology proposals. J. Toxicol. Sci. 21:305-308, 1996
PubMed
7) Royer,I., Monsarrat,B., Sonnier,M. et al.:Metabolism of docetaxel by human cytochromes P450:interactions with paclitaxel and other antineoplastic drugs. Cancer Res. 56:58-65, 1996
PubMed
8) Marre, F., Sanderink, G.J., Sousa, G. et al.:Hepatic biotransformation of docetaxel (Taxotere?) in vitro:involvement of the CYP3A subfamily in humans. Cancer Res. 56:1296-1302, 1996
PubMed
9) Rowinsky,E.K., Citardi,M.J., Noe,D.A. et al.:Sequence-dependent cytotoxic effects due to combinations of cisplatin and the antimicrotubule agents taxol and vincristine. J. Cancer Res. Clin. Oncol. 119:727-733, 1993
PubMed
10) Rowinsky,E.K., Gilbert,M.R., McGuire,W.P. et al.:Sequences of taxol and cisplatin:a phase I and pharmacological study. J. Clin. Oncol. 9:1692-1703, 199
 
11) Prank,L.C., Schellens,J.H.M., Planting, A.S.T. et al.:Phase I and pharmacologic study of docetaxel and cisplatin in patients with advanced solid tumors. J. Clin. Oncol. 15:1071-1079, 1997
 
12) Grossman,S.A., Sheidler, V.R. and Gilbert,M.R.:Decreased phenytoin levels in patients receiving chemotherapy. Am. J. Med. 87:505-510, 1989
PubMed
13) Neef,C. and de Voogd-van der Straaten,I.:An interaction between cytostatic and anticonvulsant drugs. Clin. Pharmacol. Ther. 43:372-375, 1988
PubMed
14) Saka,H., Shimokata,K., Yoneda,S. et al.:Irinotecan and concurrent radiotherapy in locally advanced non-small cell lung cancer:a phase II study of Japan Clinical Oncology Group (JCOG9504). Proc. Am. Soc. Clin. Oncol. 16:447, 1997
 
P.334 掲載の参考文献
1) Blumenschein, G.R., Cardenas, J.O., Livingston, R.B. et al.:5-fluorouracil, adriamycin and cyclophosphamide (FAC) combination chemotherapy for metastatic breast cancer. Clin. Res. 23:336-338, 1975
 
2) Bonadonna, G., Valagussa, P., Rossi, A. et al.:Ten-year experience with CMF-based adjuvant chemotherapy in resectable breast cancer. Breast Cancer Res. Treat. 5:95-115, 1985
PubMed
3) 神田和弘, 山県淳, 竹中賢治ほか:再発, 進行乳癌に対する5-FU, Adriamycin, Cyclophosphamide (FAC療法) の効果. 癌と化学療法 8:749-755, 1981
Medical*Online
4) Sasaki, Y., Ohtsu, Y., Shimada, Y. et al.:Simultaneous administration of CPT-11 and fluorouracil:alteration of the pharmacokinetics of CPT-11 and SN-38 in patients with advanced colorectal cancer. J. Natl. Cancer Inst. 86:1096-1098, 1994
 
5) Schneider, Y.J, Baurain, R., Zenebergh, A. et al.:DNA binding parameters of daunorubicin and doxorubicin in the conditions used for study the interaction of anthracycline-DNA complexes with cells in vitro. Cancer Chemother. Pharmacol. 2:7-10, 1979
 
6) Tewey, K.M., Rowe, T.C., Yang, L. et al.:Adriamycin-induced DNA damage mediated by mammalian DNA topoisomerase II. Science 216:466-468, 1984
 
7) Arcamone, F., Penco, S., Vigevoni, A. et al.:Synthesis and antitumor propaties of new glycosides of daunomycinone and adriamycinone. J. Med. Chem. 18:703-707, 1975
PubMed
8) Watanabe, T., Miya, T., Fukutomi, T. et al.:Phase I study of high-dose epirubicin (EPI) and cyclophosphamide(CPA) with rG-CSF for metastatic breast cancer. Proc. Am. Soc. Clin. Oncol. 11:88, 1992
 
9) Bruno, N.A. and Slate, D.L.:Effect of exposure to calcium entry blockers on doxorubicin accumulation and cytotoxicity in multi-drug resistant cells. J. Natl. Cancer Inst. 82:419-424, 1990
 
10) Clarke, L. and Waxman, D.J.:Oxidative metabolism of cyclophos-phamide:identification of the hepatic monooxygenase catalysts of drug activation. Cancer Res. 49:2344-2350, 1989
 
11) Cagnoni, P.J. and Matthes, S.:Ondansetron significantly reduces the area under the curve (AUC) of cyclophosphamide (CPA) and cis-platin (CDDP). Proc. Am. Soc. Clin. Oncol. 14:462, 1995
 
12) Beretta, G. et al.:Mitomycin C. In:Pharmacology and Clinical Uses, Minerva Medica Publ., Turin, 1990, p.178
 
13) Nishiyama, M., Saeki, S., Aogi, K. etal.:Relevance of DT-diaphorase activity to mitomycin C (MMC) efficacy on human cancer cells:differences in in vitro and in vivo systems. lnt. J. Cancer 53:1013, 1993
 
14) Romero, M.G., Rabinovich, C. T., Vallejo, J. F. et al.:Vinorelbine as first-line chemotherapy for metastatic breast carcinoma. J. Clin. Oncol. 12:336-341, 1994
 
15) Gasparini, G., Caffo, O., Barni, S. et al.:Vinorelbine is an active antiproliferative agent in pretreated advanced breast cancer patients:a phase II study. J. Clin. Oncol. 12:2094-2101, 1994
PubMed
16) Leveque, D., Jehl, F., Quoix, E. et al.:Clinical pharmacokinetics of vinorelbine alone and combined with cisplatin. J. Clin. Pharmacol. 32:1096-1098, 1992
PubMed
17) Rowinsky, E.K., Cazenave, L. A. and Donehower, R. C.:Taxol:a novel investigational antimicrotublue agent. J. Natl. Cancer Inst. 82:1247-1259, 1990
PubMed
18) Ringel, I.:Studies with RP 56976 (taxotere):a semisynthetic analog of taxol. J. Natl. Cancer Inst. 83:288-291, 1991
PubMed
19) Swain, S.M., Lippman, M. E. and Egan, E. F. et al.:Fluorouracil and high dose leucovorin in previously treated patients with metastatic breast cancer. J. Clin. Oncol. 7:890-894, 1989
PubMed
20) Yamamoto, T., Terada, N, Nishizawa, Y. et al.:Angiostatic activities of medroxyprogesterone acetate and its analogues. Int. J. Cancer 56:393-399, 1994
PubMed
21) Buzdar, A.U.:Current status of endocrine treatment of carcinoma of the breast. Semin. Surg. Oncol. 5:55-61, 1990
 
22) Brodie, A. M., Banks, P. K., Inkster, S. E. et al.:Aromatase and other inhibitors in breast and prostatic cancer. J. Steroid Biochem Mol. Biol. 37:1043-1048, 1990
PubMed
23) Wakeling, A.E.:Regulatory mechanisms in breast cancer, steroidal pure antiestrogens. Cancer Treat. Res. 53:239-257, 1991
PubMed
24) Ebbs, S.R., Roberts, J. and Baum, M.:Response to toremifene (Fc-1157a) therapy in tamoxifen failed patients with breast cancer. Preliminaly communication. J. Steroid Biochem. 36:239, 1990
 
25) Bhatnagar, A.S. and Hausler, A.:Highly selective inhibition of estrogen biosynthesis by CGS 20267, a new non-steroidal aromatase inhibitor. J. Steroid. Biochem. Mol. Biol. 37:1021-1027, 1990
PubMed
26) Wolmark, N. and Fisher, B.:Adjuvant therapy in primary breast cancer. Surg. Clin. North Am. 65:161-180, 1985
PubMed
27) Swain, S.M., Sorace, R.A., Bagley, C. S. et al.:Neoadjuvant chemotherapy in the combined modality approach of locally advanced metastatic breast cancer. Cancer Res. 47:3889-3894 1987
 
28) Buzdar, A.U., Kau, S.W., Smith, T. L. et al.:Ten year results of FAC:adjuvant chemotherapy trials in breast cancer. Am. J. Clin. Oncol. 12:123-128, 1989
PubMed
29) 医薬相互ハンドブック, 厚生省薬務局企画室監修, 日本薬剤師会編, 薬業時報社, 東京, 1992
 
P.346 掲載の参考文献
1) Chambers, S.K., Flynn, S.D., Del Prete, S.A. et al.:Bleomycin, vincristine, mitomycin C, and cis-platinum in gynecologic squamous cell carcinomas:a high incidence of pulmonary toxicity. Gynecol. Oncol. 32:303-309, 1989
PubMed
2) Buxton, E.J., Meanwell, C.A., Hilton, C. et al.:Combination bleomycin, ifosfamide, and cisplatin chemotherapy in cervical cancer. J. Natl. 1 Cancer Inst. 81:359-361, 1989
 
3) Cyclophosphamide plus cisplatin versus cyclophosphamide, doxorubicin, and cisplatin chemotherapy of ovarian carcinoma:a meta-analysis. The Ovarian Cancer Meta-Analysis Project. J. Clin. Oncol. 9:1668-1674, 1991
PubMed
4) Ozols, R.F.:Current status of chemotherapy for ovarian cancer. Semin. Oncol. 22(5 suppl. 12):S61-66, 1995
 
5) Alberts, D.S., Liu, P.Y., Hannigan, E.V. et al.:Intraperitoneal cisplatin plus intravenous cyclophosphamide versus intravenous cisplatin plus intravenous cyclophosphamide for stage III ovarian cancer. N. Engl. J. Med. 335:1950-1955, 1996
PubMed
6) McGuire, W.P., Hoskins, W.J., Brady, M.F. et al.:Comparison of combination therapy with paclitaxel and cisplatin versus cyclophosphamide and cisplatin in patients with suboptimal stage III and stage IV ovarian cancer:a Gynecologic Oncology Group study. Semin. Oncol. 24(1 suppl. 2):S2-13-S2-16, 1997
 
7) Williams, S., Blessing, J.A., Liao, S.Y. et al.:Adjuvant therapy of ovarian germ cell tumors with cisplatin, etoposide, and bleomycin:a trial of the Gynecologic Oncology Group. J. Clin. Oncol. 12:701-706, 1994
 
8) Homesley, H.D.:Development of single-agent chemotherapy regimens for gestational trophoblastic disease. Reprod. Med. 39:185-192, 1994
PubMed
9) Berkowitz, R.S. and Goldstein, D.P.:Gestational trophoblastic disease. Cancer 76(10 suppl.):S2079-S2085, 1995
 
10) Rustin, G.J., Newlands, E.S., Begent, R.H. et al.:Weekly alternating etoposide, methotrexate, and actinomycin/vincristine and cyclophosphamide chemotherapy for the treatlnent of CNS metastases of choriocarcinoma. J. Clin. Oncol. 7:900-903, 1989
PubMed
P.356 掲載の参考文献
1) Sternberg, C.N., Yagoda, A., Scher,H.I. et al.:Preliminary results of M-VAC (methotrexate, vinblastine, doxorubicin, cisplatin) for transitional cell carcinoma of the urothelium. J.Urol. 133:403-407, 1985
PubMed
2) Sternberg, C.N., Yagoda, A., Scher,H.I. et al.:M-VAC (meth-otrexate, vinblastine, doxorubicin and cisplatin) for advanced transitional cell carcinoma of the urothelium. J.Urol. 139:461-469, 1988
 
3) Yagoda, A.:The role of cisplatin-based chemotherapy in advanced urothelial tract tumor. Semin. Oncol. 16:98-104, 1989
PubMed
4) Logothetis,C.J., Swanson, D., Amato, R. et al.:Optimal delivery of perioperative chemotherapy:preliminary results of a randomized, prospective, comparative trial of preoperative and postoperative chemotherapy for invasive bladder carcinoma. J.Urol. 155:1241-1245, 1996
 
5) Millikan, R. and Dinney, C.:The role of chemotherapy in the management of the patient with T3b bladder cancer. Semin. Urol. Oncol. 14:81-85, 1996
PubMed
6) Labrie,F.:Complete androgen blockade for the treatment of prostatic cancer. In:Important Advances in Oncology 1985, ed. by DeVita, V.T. Jr., Hellerman, S. and Rosenberg, S.A, J.B Lippincot Co., Philadelphia, 1985, pp. 193-217
 
7) Crawford, E.D.:A controlled trial of leuprolide with and without flutamide in prostatic carcinoma. N. Engl. J. Med. 321:419-424, 1989
PubMed
8) Denis, L.J.:Goserelin acetate and flutamide versus bilateral orchiectomy:a phase 3 EORTC trial (30853). Urology 42:119-130, 1993
PubMed
9) Izbicki, R.M. et al.:Combination of adriamycin and cyclophosphamide in the treatment of metastatic prostatic carcinoma:a phase 2 study. Cancer Treat. Rep. 63:999-1001, 1979
PubMed
10) Logothetis, C.J.:Doxorubicin, mitomycin C and 5-fluorouracil(DMF) in the treatment of metastatic hormonal refractory adenocarcinoma of the prostate, with a note on the staging of metastatic prostate cancer. J. Clin. Oncol. 1:368-375, 1983
PubMed
11) Drelichman, A.:Evaluation of cyclophosphamide, adriamycin, and cis-platinum (CAP) in patients with disseminated prostatic carcinorna:aphase 2 study. Am. J. Clin. Oncol. 8:255-259, 1985
 
12) 吉本純, 那須保友, 赤木隆文ほか:進行StageD前立腺癌に対する Vincristine, Ifosfamide,Peplomycin 併用療法. 日泌尿会誌 76:1-9, 1985
 
13) 吉本純, 三枝道尚, 越智淳三ほか:未治療StageD前立腺癌症例に対する化学療法の意義. 西日泌尿 49:1105-1108, 1987
 
14) Finley, R.S.:Drug interaction in the oncology patient. Semin. Oncol. Nursing 8:95-101, 1992
PubMed
15) Young, L. Y., Anne , M. and Kimble, K.:Antineoplastic drug interactions. In:Applied Therapeutics:The Clinical Use of Drugs (Drug Interaction of Updates quarlely), Applied Therapeutics Inc., Vancuver, 1993, pp.401-421
 
P.368 掲載の参考文献
1) Alberts, D.S. and van Daalen Wetters, T.:The effect of phenobarbital on cyclophosphamide antitutumor activity. Cancer Res. 36:2785-2789, 1976
PubMed
2) Donelli, M.G., Colombo, T. and Garattini, S.:Effect of cyclophosphamide on the activity and distribution of penobarbital in rats. Biochem. Pharmacol. 22:2609-2614, 1973
 
3) Gryn, J., Gordon, R., Bapat, A. et al.:Pentostatin increases the acute toxicity of high dose cyclophosphamide. Bone Marrow Transplant. 12:217-220, 1993
PubMed
4) Dodion, P., Riggs, C.E.Jr., Akman,S.R. et al.:Interactions between cyclophosphamide and adriamycin metabolism in rats. J. Pharmacol. Exp. Therapeutics 229:51-57, 1984
 
5) Balis, F.M.:Pharmacokinetics drug interactions of commonly used anticancer drugs. Clin. Pharmacokinet. 11:223-235, 1986
PubMed
6) Bagley, C.M.Jr., Bostick, F.W. and DeVita, V.T.Jr.:Clinical pharmacology of cyclophosphamide. Cancer Res. 33:226-233, 1973
PubMed
7) Loadman, P.M. and Bibby, M.C.:Pharmacokinetic drug interactions with anticancer drugs. Clin. Pharmacokinet. 26:486-500, 1994
PubMed
8) Witten, J.W. et al.:The pharmacokinetics of cyclophosphamide in man after treatment with allopurinol. Acta Pharmacol. Toxicol. 46:392-394, 1980
 
9) 西川清広, 草間香里, 浴本久雄ほか:Etoposideと他抗癌剤との併用効果の基礎的検討. 癌と化学療法 16:3739-3745, 1989
Medical*Online
10) 南博信, 佐々木康綱:抗癌剤と他剤との薬物相互作用. Prog. Med. 16:2349-2354, 1996
Medical*Online
11) Lum, B.L, Kaubissch, S., Yahanda, A.M. et al.:Alteration of etoposide pharmacokinetics and pharmacodynamics by cyclosporine in a phase I trial to modulate multidrug resistance. J. Clin. Oncol. 10:1635-1642, 1992
 
12) Zager, R.F., Frisby, S.A. and Oliverio, V.T.:The effects of antibiotics and cancer chemotherapeutic agents on cellular transport and antitumor activity of methotrexate in L1210 muline leukemia. Cancer Res. 33:1670-1676, 1973
PubMed
13) 古江尚:薬剤の相互作用. 抗癌剤を中心に. 癌と化学療法12:2231-2236, 1985
 
14) Gabrielli, A., Leoni, P., Danieli, G. et al.:Methotrexate and non-steroidal anti-inflammatory drugs. Br. Med. J. 294:776, 1987
 
15) Maiche, A.G.:Acute renal failure due to concomitant action of methotrexate and indomethacin. Lancet (June 14):1390, 1986
 
16) Singh, R.R., Malaviya, A.N., Pandey, J.N. et al.:Fatal interaction between methotrexate and naproxen. Lancet (June 14):1390, 1986
 
17) Daly, H., Boyle, J., Roberts, C. et al.:Interaction between methotrexate and non-steroidal anti-inflammatory drugs. Lancet (March 8):557, 1986
 
18) Thyss, A., Milano, G., Kuber, J. et al.:Clinical and pharmacokinetic evidence of a life-threatening interaction between methotrexate and ketoprofen. Lancet (Feb 1):256, 1986
 
19) Goodman, L.S. and Gilman, A.:The Pharmacological Basis of Therapeutics. 1975
 
20) Ferrazzini, G., Klein, J., Sulh, H. et al.:Interaction between trimethoprim-sulfamethoxazole and methotrexate in children with leukemia. J. Pediatr. 117:823-826, 1990
PubMed
21) Burton, N.K. and Aherne, G.W.:The effect of cotrimoxazole on the absorption of orally administered 6-mercaptpurine in the rat. Cancer Chemother. Pharmacol. 16:83-84, 1986
PubMed
22) Yusa, K. and Tsuruo, T.:Reversal mechanism of multidrug resistance by verapamil:direct binding of verapamil to P-glycoprotein on specific sites and transport of verapamil outward across the plasma membrane of K562/ADM cells. Cancer Res. 49:5002-5006, 1989
 
23) 岩本差由利:抗悪性腫瘍薬を取り扱う際の反応および相互作用. 日本薬剤師会雑誌 20:111-115, 1984
 
24) Zhou, X.J., Zhou-Pan, X.R., Gauthier, T. et al.:Human liver microsomal cytochrome P450 3A isozymes mediated vincristine biotransformation. Biochem. Pharmacol. 45:853-861, 1993
PubMed
25) Mauer, A.M.:Master's two-step test. Ann. Intern. Med. 75:804-805, 1971
 
26) Simizu, T., Kubota, M., Adachi, S. et al.:Pre-treatment of a human T-lymphoblastoid cell line with L-asparaginase reduces etoposide-induced DNA strand breakage and cytotoxicity. Int. J. Cancer 50:644-648, 1992
 
27) Jolivet, J., Cole, D.E., Holchenberg, J.S. et al.:Prevention of methotrexate cytotoxicity by asparaginase inhibition of methotrexate polyglutamate formation. Cancer Res. 45:217-220, 1985
 
28) Whitecar, J.P., Bodey, G.P., Harris, J.E. et al.:L-asparaginase. N. Engl. J. Med 282:732-734, 1970
 
29) Fernberg, J.O., Lewensohn, R. and Skog, S.:Interaction of melphalan and dexamethazone in a human myeloma cell line. Anti-cancer Drugs 2:565-570, 1991
 
30) Bitran, J.D.:Doxorubicin cardiotoxicity and melphalan. Ann. lntern. Med. 95:243-244, 1981
PubMed
31) Sviland, L., Robinson, A., Proctor, S.J. et al.:Interaction of cimetidine with oral melphalan. A pharmacokinetic study. Cancer Chemother. Pharmacol. 20:173-175, 1987
PubMed
32) 和田端紀, 千葉博暁, 中野真也ほか:多剤耐性型癌細胞に対する制癌薬の制癌作用のフェニトインによる選択的増強. 医薬品相互作用研究 20:3-15, 1996
 
33) Baeyens, J.M.:Interactions between calcium channel blockers and non-cardiovascular drugs. Interactions with anticancer drugs. Pharmacol. Toxicol. 63:1-7, 1988
PubMed
34) 木矢克造, 魚住徹, 栗栖薫ほか:悪性グリオーマに対する放射線・MCNU・Interferon‐β療法. 癌と化学療法17:221-226, 1990
 
P.378 掲載の参考文献
1) Velasquez, W.S., Cabanillas, F., Salvador, P. et al.:Effective salvage therapy for lymphoma with cisplatin in combination with high-dose ara-C and dexamethazone (DHAP). Blood 71:117-122, 1988
 
2) Nierenberg, D.W.:Competitive inhibition of methotrexate accumulation in rabbit kidney slices by nonsteroidal anti-inflammatory drugs. J. Pharmacol. Exp. Ther. 226:1-6, 1983
PubMed
3) Thyss, A., Milano, G., Kubar, J. et al.:Clinical and pharmacokinetic evidence of a life-threatening interaction between methotrexate and ketoprofen. Lancet i:256-258, 1986
PubMed
4) Daly, H., Boyle, J., Roberts, C. et al.:Interaction between methotrexate and non-steroidal anti-inflammatory drugs. Lancet i:557, 1986
PubMed
5) Maiche, A.G.:Acute renal failure due to concomitant action of methotrexate and indomethacin. Lancet i:1390, 1986
PubMed
6) Singh, R.R., Malaviya, A.N., Pandey, J.N. et al.:Fatal interaction between methotrexate and naproxen. Lancet i:1390, 1986
PubMed
7) Thyss, A., Milano, G., Renee, N. et al.:Severe interaction between methotrexate and a macrolide-like antibiotic. J. Natl. Cancer Inst. 85:582-583, 1993
 
8) Grever, M., Kopecky, K., Foucar, M.K. et al.:Randomized comparison of pentostatin versus interferon alfa-2a in previously untreated patients with hairy cell leukemia.J. Clin. Oncol. 13:974-982, 1995
PubMed
9) Tobinai, K., Shimoyama, M., Inoue, S. et al.:Phase I study of YK-176 (2'-deoxycoformycin) in patients with adult T-cell leukemia-lymphoma. Jpn. J. Clin. Oncol. 22:164-171, 1992
PubMed
10) Miser, J.S., Roloff, J., Blatt, J. et al.:Lack of significant activity of 2'-deoxycoformycin alone or in combination with adenine arabinoside in relapsed childhood acute lymphoblastic leukemia:a randomized phase II trial from the Childrens Cancer Study Group. Am. J. Clin. Oncol. 15:490-493, 1992
PubMed
11) Gryn. J., Gordon, R., Bapat, A. et al.:Pentostatin increases the acute toxicity of high dose cyclophosphamide. Bone Marrow Transplant. 12:217-220, 1993
PubMed
12) Steinmetz, J.C., DeConti, R., Ginsburg, R. et al.:Hypersensitivity vasculitis associated with 2-deoxycoformycin and allopurinol therapy. Am. J. Med. 86:498-499, 1989
PubMed
P.388 掲載の参考文献
1) 山本明史:フェロン・DAV併用療法の基礎と臨床. Skin Cancer 11:358-366, 1996
 
2) 山崎直也, 佐々木英也, 早坂健一ほか:進行期悪性黒色腫に対するcisplatin+dacarbazine+vindesine療法の効果. Skin Cancer 4:362-366, 1989
 
3) Fierro, MT., Bertero, M., Novelli, M. et al.:Therapy fo metastatic melanoma:effective combination of dacarbazine, carmustine, cisplatin and tamoxifen. Melanoma Res. 3:127-131, 1993
 
4) Guthrie, T.H., Porubsky, E.S., Luxenberg, M. N. et al.:Cisplatin-based chemotherapy in advanced basal and squamous cell carcinomas of the skin results in 28 patients including 13 patients receiving multimodality therapy. J. Clin. Oncol. 8:342-346, 1990
PubMed
5) Sadek, H., Azli, N., Wendling, J.L. et al.:Treatment of advanced squamous cell carcinoma of the skin with cisplatin, 5-fluorouracil, and bleomycin. Cancer 66:1692-1696, 1990
PubMed
6) 池田重雄, 石原和之, 大浦武彦ほか:有棘細胞癌および悪性黒色腫に対する塩酸イリノテカン (CPT-11) の後期第II相臨床試験. Skin Cancer 8:503-513, 1993
 
P.399 掲載の参考文献
1) Rosen, G.:An opinion supporting the role of high-dose methotrexate in the treatment of osteosarcoma. In:Osteosarcoma in Adolescents and Young Adults, ed. by Humphrey, G.B., Kluwer Academic Publishers,Boston,1993, pp.49-54
 
2) Rosen, G.:Preoperative (neoadjuvant) chemotherapy for osteogenic sarcoma:a ten year experience. Orthopedics 8:659-664, 1985
 
3) 武内章二, 葛西千秋, 櫛田喜輝ほか:四肢悪性骨腫瘍に対する患肢温存療法-術前持続動注療法とreduction surgeryについて-. 臨床整形外科 22:1163-1172, 1987
 
4) Ewing, J.:Diffuse endothelioma of bone. Proc. NY Pathol. Soc. 21:17-24, 1921
 
5) Rosen, G., Caparros, B., Nirenberg, A. et al.:Ewing's sarcoma:ten year experience with adjuvant chemotherapy. Cancer 47:2204-2213, 1981
PubMed
6) Jurgen, H., Exner, U., Kuhl, J. et al.:High dose ifosfamide with mesna uroprotection in Ewing's sarcoma. Cancer Chemother. Pharmacol. 24:S40-S44, 1989
 
7) Bacci, G., Picci, P., Ruggieri, P. et al.:No advantages in the addition of ifosfamide and VP-16 to the standard four drug regimen in the maintenance phase of neoadjuvant chemotherapy of Ewing's sarcoma of bone:results of two sequential studies. J. Chemother. 5:247-257, 1993
 
8) Yap, B.S., Baker, L.H., Sinkovics, J.G. et al.:Cyclophosphamide, vincristine, adriamycin, and DTIC (CYVADIC) combination chemotherapy for the treatment of advanced sarcomas. Cancer Treatment Reports 64:93-98, 1980
PubMed
9) Baker, L.H., Frank, J., Fine, G. et al.:Combination chemotherapy using adriamycin, DTIC, cyclophosphamide, and actinomycin-D for advanced soft tissue sarcomas:a randomized comparative trial. A phase lll, Southwest Oncology Group Study. J. Clin. Oncol. 5:851-861, 1987
 
10) Crom, W.R., Pratt, C.B., Green, A.A. et al.:The effect of prior cisplatin therapy on the pharmacokinetics of high dose methotrexate. J. Clin. Oncol. 2:655-661, 1984
 
11) Yap, A.K., Jani, J.J. and Luscombe, D.K.:Methotrexate toxicity coincident with packed red cell transfusions. Lancet ii:641, 1986
 
12) Canpolat, C., Pearson, P. and Jaffe, N.:Cisplatin associated hemolytic uremic syndrome. Cancer 74:3059-3062, 1994
PubMed
13) Meyer, W.H., Ayers, D., McHaney, V.A. et al.:Ifosfamide and exacerbation of cisplatin induced hearing loss. Lancet 341:754-755, 1993
PubMed
14) 永露巌, 小林尚志, 内山典明ほか:骨肉腫に対するシスプラチン動注療法. 癌と化学療法 17:47-52, 1990
 
15) 米瀬淳二, 辻井俊彦, 田利清信:Heparin持続投与によるCis-platinum の腎障害軽減効果. 腎と透析 29:669-672, 1990
 
16) Salem, P.A., Jabboury, K.W. and Khalil, M.F.:Severe nephrotoxicity:a probable complication of cis-dichlorodiammineplatinum(II) and cephalothin-gentamicin therapy. Oncology 39:32-32, 1982
 
17) Ershler, W.B., Gilchrist, K.W. and Citrin, D.L.:Adriamycin enhancement of cyclophosphamide induced bladder injury. J. Urol. 123:121-122, 1980
PubMed
18) Goren, M.P., Wright, R.K., Pratt, C.B. et al.:Potentiation of ifosfamide neurotoxicity, hematoxicity, and tubular nephrotoxicity by prior cis-diamminedichloroplatinum(II) therapy. Cancer Res. 47:1457-1460, 1987
 
19) Harvey, V.J., Slevin, M.L., Dilloway, M.R. et al.:The influence of cimetidine in the pharmacokinetics of 5-fluorouracil. Br. J. Clin. Pharmacol. 18:421-430, 1984
PubMed
20) Bardakji, Z., Jolivet, J. and Langelier, Y.:5-fluorouracil metronidazole combination therapy in metastatic colorectal cancer. Clinical, pharmacokinetic and in vitro cytotoxicity studies. Cancer Chemother. Pharmacol. 18:140-144, 1986
PubMed
21) Wajima, T. and Mukhopadhyay, P.:Possible interactions between warfarin and 5-fluorouracil. Am. J. Hemat. 40:238, 1992
PubMed
22) Hildebrand, J. and Kenis, Y.:Vincristine neurotoxicity. N. Engl. J. Med. 287:517, 1972
PubMed

Part4: 薬物間相互作用を回避するためのソフトと八ード

P.419 掲載の参考文献
1) 澤田康文, 高長ひとみ, 伊賀立二:医薬品添付文章の「薬物間相互作用」欄は今後どうあるべきか? 薬局47:1535-1565, 1996
 
2) 澤田康文:特集によせて, 薬物間相互作用に関する研究のありかた. 総合特集:薬物間相互作用と医薬品の適正使用. 月刊薬事 (2月臨時増刊号) 38:459-464, 1996
 
3) 澤田康文, 伊賀立二:Part 3:薬物間相互作用研究の問題点と今後の展望, 大学における研究者からの提言 (その1). 総合特集:薬物間相互作用と医薬品の適性使用. 月刊薬事 (2月臨時増刊号) 38:725-750, 1996
 
4) 澤田康文編, 伊賀立二監修:総合特集:薬物間相互作用と医薬品の適性使用. 月刊薬事 (2月臨時増刊号) 38:449-905, 1996
 
5) 澤田康文著, 伊賀立二監修:薬剤予測学入門. 薬業時報社, 東京, 1993
 
6) 澤田康文著, 伊賀立二監修:薬の飲み合わせ. 講談社ブルーバックス, 1996
 
7) 伊賀立二監修, 澤田康文編:一目でわかる薬物間相互作用. 文光堂, 東京 , 1996
 
8) 澤田康文, 伊賀立二編:特集/臨床医のための薬物間相互作用. 治療 76:2213-2372, 1994
 
9) 澤田康文, 山田安彦著, 伊賀立二監修:シリーズ:GPのためのファーマコロジー (1)～(29). Clinician, エーザイ, 1993-1996
 
10) 澤田康文著, 伊賀立二監修:臨床医のための薬の相互作用とそのマネージメント. 南山堂, 東京, 1996
 
11) 澤田康文, 山田安彦, 伊賀立二:薬物療法のQuality-of-Lifeへの影響;その実態, 予測と制御-テルフェナジンと他の薬物との相互作用によるQOLの悪化;テルフェナジンによる心血管系副作用. 月刊薬事 36:1293, 1994, 36:1563, 1994, 36:2051, 1994
 
P.433 掲載の参考文献
1) 伊賀立二, 澤田康文:とくに注意を要する薬物間相互作用. 医学のあゆみ 136:442-601, 1992
 
2) 澤田康文, 伊賀立二:薬剤の相互作用. 研修医ノート, 診断と治療社, 東京, 1995, pp.592-595
 
3) 山田安彦, 伊賀立二:薬物‐薬物間相互作用. 臨床麻酔 20:1112-1118 1996
 
4) 伊賀立二, 山田安彦, 澤田康文:特集「医療用医薬品添付文書」はどうあるべきか:薬物間相互作用と医薬品添付文書. 薬局 47:1517-1531, 1996
 
5) 伊賀立二:平成7年度厚生科学研究, 医薬品添付文書の見直し等に関する研究,-相互作用欄の見直し-, 報告書. 臨床評価 24:125-146, 1996
 
6) 溝上直子, 松山恭子, 山田安彦ほか:新たな外来業務の展開6‐外来患者への能動的薬品情報提供 (2) 『お薬説明カード』による薬品情報提供-相互作用.副作用の回避へ向けて-. 薬局 48:841-849, 1997
 
7) 鈴木あやな, 溝上直子, 折井孝男ほか:患者への薬品情報の適正な提供-「処方カード」を利用した処方情報の提供-. JJSHP 31:199-205, 1995
 
8) 高柳理早, 松山恭子, 伊賀立二ほか:新たな外来業務の展開4-「お薬手帳」を活用した患者自身による薬歴の一元管理-患者本位の適正使用の実現へ. 薬局 48:78-95, 1997
 

付

P.446 掲載の参考文献
1) Levy, M. H.:Pharmacological treatment of cancer pain. N. Engl. J. Med. 335:1124-1132, 1996
PubMed
2) Portenoy, R. K., Miransky, J., Thaler, H. T. et al.:Pain in ambulatory patients with lung or colon cancer:prevalence, characteristics, and effect. Cancer 70:1616-1624, 1992
PubMed
3) Grond, S., Zech, D., Diefenbach, C. et al.:Prevalence and pattern of symptoms in patients with cancer pain:a prospective evaluation of 1635 cancer patients referred to a pain clinic. J. Pain Symptom Manage. 9:372-382, 1994
PubMed
4) Schug, S. A., Zech, D. and Dorr, U.:Cancer pain management according to WHO analgesic guidelines. J. Pain Symptom Manage. 5:27-32, 1990
PubMed
5) Takeda, F.:Japan:status of cancer pain and palliative care. J. Pain Symptom Manage. 12:118-120, 1996
PubMed
6) 風祭元, 中込和幸:医薬品による精神障害. 神経精神薬理 10:5-24, 1988
 
7) Bruera, E., Miller, L., McCallion, J. et al.:Cognitive failure in patients with terminal cancer:a prospective study. J. Pain Symptom Manage. 7:192-195, 1992
 
8) Akechi, T., Uchitomi, Y., Okamura, H. et al.:Usage of haloperidol for delirium in cancer patients. Support Care Cancer 4:390-392, 1996
PubMed
9) 柴崎守和, 染矢俊幸, 高橋三郎:抗精神病薬の動態. 臨床精神医学 22:110-118, 1993
 
10) Kapur, S., Remington, G., Jones, C. et al.:High levels of dopamine D2 receptor occupancy with low-dose haloperidol treatment:a PET study. Am. J. Psychiatry 153:948-950, 1996
PubMed
11) Polland, H., Llorens, C., Schwartz, J. C. et al.:Localization of opiate receptors and enkephalins in rat striatum in relationship with the nigrostrial dopaminergic system:lesion studies. Brain Res. 151:392-398, 1978
 
12) Walsh, T. D.:Antidepressants in chronic pain. Clin. Neztropharmacol. 6:271-295, 1983
PubMed
13) Pilowsky, I., Hallett, E. C., Bassett, D. L. et al.:A controlled study of amitriptyline in the treatment of chronic pain. Pain 14:169-179, 1982
PubMed
14) Portenoy, R. K.:Drug treatmernt of pain syndromes. Semin. Oncol. 7:139-149, 1987
 
15) Biegon, A. and Samuel, D.:Interaction of tricyclic antidepressants with opiate receptors. Biochem. Pharmacol. 29:460-462, 1980
PubMed
16) Sierralta, F., Pinardi, G., Mendez, M. et al.:Interaction of opioids with antidepressant-induced antinociception. Psychopharmacology 122:374-378, 1995
PubMed
17) Feinmann, C.:Pain relief by antidepressants:possible modes of action. Pain 23:1-8, 1985
PubMed
18) Sternbach, R.:The need for an animal model of chronic pain. Pain 2:2-4, 1976
PubMed
19) Spiegel, D., Sands, S. and Koopman, C.:Pain and depression in patients with cancer. Cancer 74:2570-2578, 1994
PubMed
20) Kelsen, D., Portenoy, R. K., Thaler, H. T. et al.:Pain and depression in patients with newly diagnosed pancreas cancer. J. Clin. Oncol. 13:748-755, 1995
PubMed

書評

最近チェックした商品履歴

Loading...